U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1	2002/0049173 A1	04-25-2002	Bennett et al.				
	2	2002/0071826 A1	06-13-2002	Tamarkin et al.				
	3	2002/0081577 A1	06-27-2002	Kilkuskie et al.				
	4	2002/0081736 A1	06-27-2002	Conroy et al.				
	5	2002/0102267 A1	08-01-2002	Lu et al.				
	6	2002/0147332 A1	10-10-2002	Kaneko				
	7	2002/0156235 A1	10-24-2002	Manoharan et al.				
	8	2002/0162126 A1	10-30-2002	Beach et al.				
	9	2002/0165189 A1	11-07-2002	Crooke				
	10	2002/1051512 A1	10-17-2002	Peyman et al.				
	11	2003/0004325 A1	01-02-2003	Cook et al.				
	12	2003/0027780 A1	02-06-2003	Hardee et al.				
	13	2003/0096286 A1	05-22-2003	Crooke				
	14	2003/0096287 A1	05-22-2003	Crooke				
	15	2003/0096784 A1	05-22-2003	Crooke				
	16	2003/0119777 A1	06-26-2003	Crooke				
	17	2003/0158403 A1	08-21-2003	Manoharan et al.				
	18	2003/0166282 A1	09-04-2003	Brown et al.				
	19	2003/0175906 A1	09-18-2003	Manoharan et al.				
	20	2003/0187240 A1	10-02-2003	Cook et al.				
	21	2003/0190635 A1	10-09-2003	McSwiggen				
	22	2003/0207804 A1	11-06-2003	Manoharan et al.				
	23	2003/0224377 A1	12-04-2003	Wengel et al.				
	24	2004/0001811 A1	01-01-2004	Kreutzer et al.				
	25	2004/0009938 A1	01-15-2004	Manoharan et al.				
	26	2004/0014957 A1	01-22-2004	Eldrup et al.				

U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	27	2004/0102618 A1	05-27-2004	Crooke et al.				
	28	2004/0171033 A1	09-02-2004	Baker et al.				
	29	2004/0259247 A1	12-23-2004	Tuschl et al.				
	30	2005/0020525 A1	01-27-2005	McSwiggen et al.				
	31	2005/0080246 A1	04-14-2005	Allerson et al.				
	32	2005/0164209 A1	07-28-2005	Bennett et al.				
	33	2005/0181382 A1	08-18-2005	Zamore et al.				
	34	2005/0221275 A1	10-06-2005	Bennett et al.				
	35	2005/0245474 A1	11-03-2005	Baker et al.				
	36	2005/0273868 A1	12-08-2005	Rana				
	37	2006/0127891 A1	06-15-2006	McSwiggen et al.				
	38	2007/0032446 A1	02-08-2007	Cook et al.				
	39	4,381,344	04-26-1983	Rideout et al.				
	40	4,415,732	11-15-1983	Caruthers et al.				
	41	4,426,330	01-17-1984	Sears				
	42	4,458,066	07-03-1984	Caruthers et al.				
	43	4,476,301	10-09-1954	Imbach et al.				
	44	4,500,707	02-19-1985	Caruthers et al.				
	45	4,511,713	04-16-1985	Miller et al.				
	46	4,534,899	08-13-1985	Sears				
	47	4,587,044	05-06-1986	Miller				
	48	4,605,735	08-12-1986	Miyoshi				
	49	4,667,025	05-19-1987	Miyoshi				
	50	4,668,777	05-26-1987	Caruthers et al.				
	51	4,689,320	08-25-1987	Kaji				
	52	4,725,677	02-16-1988	Koster et al.				

U. S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	53	4,760,017	07-26-1988	McCormick					
	54	4,762,779	08-09-1988	Snitman					
	55	4,789,737	12-06-1988	Miyoshi					
	56	4,824,941	04-25-1989	Gordon					
	57	4,828,979	05-09-1989	Klevan					
	58	4,835,263	05-30-1989	Nguyen					
	59	4,845,205	07-04-1989	Huynh Dinh et al.					
	60	4,849,320	07-18-1989	Irving et al.					
	61	4,849,513	07-18-1989	Smith et al.					
	62	4,876,335	10-24-1989	Yamane					
	63	4,904,582	02-27-1990	Tullis					
	64	4,924,624	05-15-1990	Suhadolnik et al.					
	65	4,948,882	08-14-1990	Ruth					
	66	4,958,013	09-18-1990	Letsinger					
	67	4,965,350	10-23-1990	Inoue et al.					
	68	4,973,679	11-27-1990	Caruthers et al.					
	69	4,981,957	01-01-1991	Lebleu					
	70	5,000,000	03-19-1991	Ingram et al.					
	71	5,013,556	05-07-1991	Woodle et al.					
	72	5,082,830	01-21-1992	Brakel					
	73	5,108,921	04-28-1992	Low et al.					
	74	5,109,124	04-28-1992	Ramathandran					
	75	5,112,963	05-12-1992	Pieles					
	76	5,118,800	06-02-1992	Fung					
	77	5,118,802	06-02-1992	Smith					
	78	5,132,418	07-21-1992	Caruthers et al.					

	Substitute for 1449/PTO			Complete if Known		
Substitute for				Application Number	10/701,265	
	PRMATION			Filing Date	11-04-2003	
STA	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	4	of	44	Attorney Docket Number	ISIS-5300	

U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	79	5,134,066	07-28-1992	Rogers et al.				
	80	5,138,045	08-11-1992	Cook				
	81	5,149,782 A	09-22-1992	Chang et al.				
	82	5,166,315	11-24-1992	Summerton et al.				
	83	5,175,273	12-29-1992	Bischofberger et al.				
	84	5,177,196	01-05-1993	Meyer, Jr. et al.				
	85	5,185,444	02-09-1993	Summerton et al.				
	86	5,188,897	02-23-1993	Suhadolnik et al.				
	87	5,194,599	03-16-1993	Froehler et al.				
	88	5,212,295 A	05-18-1993	Cook				
	89	5,213,804	05-25-1993	Martin et al.				
	90	5,214,134	05-25-1993	Weis et al.				
	91	5,214,135 A	05-25-1993	Srivastava et al.				
	92	5,214,136	05-25-1993	Lin				
	93	5,216,141	06-01-1993	Benner				
	94	5,218,105	06-08-1993	Cook				
	95	5,227,170	07-13-1993	Sullivan				
	96	5,245,022	09-14-1993	Weis				
	97	5,254,469	10-19-1993	Warren				
	98	5,258,506	11-02-1993	Urdea				
	99	5,262,536	11-16-1993	Hobbs				
	100	5,264,221	11-23-1993	Tagawa et al.				
	101	5,264,423	11-23-1993	Cohen et al				
	102	5,272,250	12-21-1993	Spielvogel				
	103	5,276,019	01-04-1994	Cohen et al				
	104	5,278,302	01-11-1994	Caruthers et al.				

	Substitute for 1449/PTO			Complete if Known		
Substitute for	1449/PTO			Application Number	10/701,265	
	RMATION			Filing Date	11-04-2003	
STA	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	5	of	44	Attorney Docket Number	ISIS-5300	

	U. S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
	105	5,286,717	02-15-1994	Cohen et al						
	106	5,292,873	03-08-1994	Rokita						
	107	5,317,098	05-31-1994	Shizuya						
	108	5,319,080	06-07-1994	Leumann						
	109	5,321,131	06-14-1994	Agrawal et al.						
	110	5,354,844	10-11-1994	Beug et al.						
	111	5,356,633	10-18-1994	Woodle et al.						
	112	5,367,066	11-22-1994	Urdea et al.						
	113	5,371,241	12-06-1994	Brush						
	114	5,391,723	02-21-1995	Priest						
	115	5,393,878	02-28-1995	Leumann						
	116	5,395,619	03-07-1995	Zalipsky et al.						
	117	5,399,676	03-21-1995	Froehler et al.						
	118	5,405,938	04-11-1995	Summerton et al.						
	119	5,405,939	04-11-1995	Suhadolnik et al.						
	120	5,414,077	05-09-1995	Lin						
	121	5,416,016	05-16-1995	Low et al.						
	122	5,416,203	05-16-1995	Letsinger						
	123	5,417,978	05-23-1995	Tari et al.						
	124	5,432,272	07-11-1995	Benner						
	125	5,434,257	07-18-1995	Matteucci et al.						
	126	5,446,137	08-29-1995	Maag						
	127	5,451,463	09-19-1995	Nelson						
	128	5,453,496	09-26-1995	Caruthers et al.						
	129	5,455,233	10-03-1995	Spielvogel et al.						
	130	5,457,187	10-10-1995	Gmeiner et al.						

	Substitute for 1449/PTO			Complete if Known		
Substitute for	1449/PTO			Application Number	10/701,265	
	RMATION			Filing Date	11-04-2003	
STA	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	6	of	44	Attorney Docket Number	ISIS-5300	

U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	131	5,459,127	10-17-1995	Felgner et al.				
	132	5,462,854	10-31-1995	Coassin et al.				
	133	5,466,677	11-14-1995	Baxter et al.				
	134	5,469,854	11-28-1995	Unger et al.				
	135	5,470,967	11-28-1995	Huie et al.				
	136	5,486,603	01-23-1996	Bahr				
	137	5,502,177	03-26-1996	Matteucci et al.				
	138	5,510,475	04-23-1996	Agrawal				
	139	5,512,295	04-30-1996	Kornberg et al.				
	140	5,512,439	04-30-1996	Hornes				
	141	5,512,667	04-30-1996	Reed				
	142	5,514,785	05-07-1996	Van Ness				
	143	5,519,126	05-21-1996	Hecht				
	144	5,521,291	05-28-1996	Curiel et al.				
	145	5,525,465	06-11-1996	Haralambidis				
	146	5,525,711	06-11-1996	Hawkins et al.				
	147	5,527,528	06-18-1996	Allen et al.				
	148	5,527,899	06-18-1996	Froehler				
	149	5,532,130	07-02-1996	Alul				
	150	5,534,259	07-09-1996	Zalipsky et al.				
	151	5,536,821	07-16-1996	Agrawal et al.				
	152	5,539,082	07-23-1996	Nielsen et al.				
	153	5,541,306	07-30-1996	Agrawal et al.				
	154	5,541,307	07-30-1996	Cook et al.				
	155	5,541,313	07-30-1996	Ruth				
	156	5,543,152	08-06-1996	Webb et al.				

U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	157	5,543,158	08-06-1996	Gref et al.				
	158	5,545,730	08-13-1996	Urdea				
	159	5,547,932	08-20-1996	Curiel et al.				
	160	5,550,111	08-27-1996	Suhadolnik et al.				
	161	5,552,538	09-13-1996	Urdea				
	162	5,552,540	09-03-1996	Haralambidis				
	163	5,556,948	09-17-1996	Tagawa et al.				
	164	5,561,225	10-01-1996	Maddry et al.				
	165	5,563,253	10-08-1996	Agrawal et al.				
	166	5,565,552	10-15-1996	Magda				
	167	5,565,555	10-15-1996	Froehler et al.				
	168	5,567,810	10-22-1996	Weis				
	169	5,571,799	11-05-1996	Tkachuk et al.				
	170	5,574,142	11-12-1996	Meyer				
	171	5,576,302 A	11-19-1996	Cook et al.				
	172	5,578,717	11-26-1996	Urdea				
	173	5,578,718	11-26-1996	Cook				
	174	5,580,575	12-03-1996	Unger et al.				
	175	5,580,731	12-03-1996	Chang				
	176	5,582,188 A	12-10-1996	Benderev et al.				
	177	5,583,020	12-17-1996	Arnold, Jr. et al.				
	178	5,585,481	12-17-1996	Arnold				
	179	5,587,361	12-24-1996	Cook et al.				
	180	5,587,371	12-24-1996	Sessler				
	181	5,587,469	12-24-1996	Cook et al.				
	182	5,591,584	01-07-1997	Chang				

	4.4.4.0./DTO			Complete if Known		
Substitute for	1449/PTO			Application Number	10/701,265	
	PRMATION			Filing Date	11-04-2003	
STA	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	8	of	44	Attorney Docket Number	ISIS-5300	

U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	183	5,591,721	01-07-1997	Agrawal et al.				
	184	5,591,722	01-07-1997	Montgomery et al.				
	185	5,594,121	01-14-1997	Froehler et al.				
	186	5,595,726	01-21-1997	Magda				
	187	5,595,756	01-21-1997	Bally et al.				
	188	5,596,086	01-21-1997	Matteucci et al.				
	189	5,596,091	01-21-1997	Switzer et al.				
	190	5,597,696	01-28-1997	Linn				
	191	5,597,909	01-28-1997	Urdea				
	192	5,599,797 A	02-04-1997	Cook et al.				
	193	5,599,923	02-04-1997	Sessler				
	194	5,599,925	02-04-1997	Torii				
	195	5,599,928	02-04-1997	Hemmi et al.				
	196	5,607,923 A	03-04-1997	Cook et al.				
	197	5,608,046	03-04-1997	Cook				
	198	5,610,289	03-11-1997	Cook et al.				
	199	5,610,300	03-11-1997	Altmann				
	200	5,612,469 A	03-18-1997	Goodchild				
	201	5,614,621	03-25-1997	Ravikumar et al.				
	202	5,618,704	04-08-1997	Sanghvi et al.				
	203	5,623,070	04-22-1997	Cook et al.				
	204	5,625,050	04-29-1997	Beaton et al.				
	205	5,627,053	05-06-1997	Usman				
	206	5,633,360	05-27-1997	Bischofberger et al.				
	207	5,634,488 A	06-03-1997	Martin, Jr.				
	208	5,635,488 A	06-03-1997	Cook et al.				

Subatituta for 1440/DTO		Complete if Known		
Substitute for 1449/PTO			Application Number	10/701,265
			Filing Date	11-04-2003
STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
			Art Unit	1635
(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
9	of	44	Attorney Docket Number	ISIS-5300
	RMATION EMENT B	RMATION DISCLOS EMENT BY APPLIC	RMATION DISCLOSURE EMENT BY APPLICANT (use as many sheets as necessary)	Application Number RMATION DISCLOSURE Filing Date First Named Inventor Art Unit (use as many sheets as necessary) Examiner Name

U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines Where Relevant Passages or Relevan Figures Appear			
	209	5,639,647 A	06-17-1997	Usman et al.				
	210	5,643,889 A	07-01-1997	Suhadolnik et al.				
	211	5,645,985	07-08-1997	Froehler et al.				
	212	5,646,265	07-08-1997	Mcgee				
	213	5,646,269	07-08-1997	Matteucci et al.				
	214	5,658,731 A	08-19-1997	Sproat et al.				
	215	5,658,873	08-19-1997	Bertsch-Frank				
	216	5,661,134 A	08-26-1997	Cook et al.				
	217	5,663,312	09-02-1997	Chaturvedula				
	218	5,663,360 A	09-02-1997	Bortolaso et al.				
	219	5,670,633	09-23-1977	Cook et al.				
	220	5,672,662 A	09-30-1997	Harris et al.				
	221	5,672,695 A	09-30-1997	Eckstein et al.				
	222	5,672,697	09-30-1997	Buhr et al.				
	223	5,677,289 A	10-14-1997	Torrence et al.				
	224	5,677,437	10-14-1997	Teng et al.				
	225	5,677,439	10-14-1997	Weis et al.				
	226	5,681,941	10-28-1997	Cook et al.				
	227	5,684,142 A	11-04-1997	Mishra et al.				
	228	5,684,143 A	11-04-1997	Gryaznov et al.				
	229	5,684,243 A	11-04-1997	Gururaja et al.				
	230	5,688,941	11-18-1997	Cook				
	231	5,698,687 A	12-16-1997	Eckstein et al.				
	232	5,700,785 A	12-23-1997	Suhadolnik et al.				
	233	5,700,920	12-23-1997	Altmann				
	234	5,714,166 A	02-03-1998	Tomalia et al.				

0 1 111 1 5	Substitute for 1449/PTO	Complete if Known			
Substitute for	Substitute for 1449/PTO		Application Number	10/701,265	
INFO	ORMATION	DISCLOS	SURE	Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
Sheet	10	of	44	Attorney Docket Number	ISIS-5300

		U. S.	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	235	5,714,331	02-03-1998	Buchardt et al.	
	236	5,716,824 A	02-10-1998	Beigelman et al.	
	237	5,719,262	02-17-1998	Buchardt et al.	
	238	5,721,218	02-24-1998	Froehler et al.	
	239	5,726,297 A	03-10-1998	Gryaznov et al.	
	240	5,750,666 A	05-12-1998	Caruthers et al.	
	241	5,750,692	05-12-1998	Cook et al.	
	242	5,763,588	06-09-1998	Matteucci et al.	
	243	5,770,713	06-23-1998	Imbach et al.	
	244	5,770,716 A	06-23-1998	Khan et al.	
	245	5,777,092 A	07-07-1998	Cook et al.	
	246	5,789,576 A	08-04-1998	Daily et al.	
	247	5,792,608	08-11-1998	Swaminathan et al.	
	248	5,792,747	08-11-1998	Schally	
	249	5,792,844 A	08-11-1998	Sanghvi et al.	
	250	5,792,847 A	08-11-1998	Buhr et al.	
	251	5,801,154 A	09-01-1998	Baracchini et al.	
	252	5,808,023 A	09-15-1998	Sanghvi et al.	
	253	5,817,781 A	10-06-1998	Swaminathan et al.	
	254	5,830,635 A	11-03-1998	Agnello	
	255	5,830,653	11-03-1998	Froehler et al.	
	256	5,837,835 A	11-17-1998	Gryaznov et al.	
	257	5,840,876 A	11-24-1998	Beigelman et al.	
	258	5,859,221 A	01-12-1999	Cook et al.	
	259	5,872,232 A	02-16-1999	Cook et al.	
	260	5,874,553	02-23-1999	Peyman et al.	

0 1 111 1 5	Substitute for 1449/PTO	Complete if Known			
Substitute for	Substitute for 1449/PTO		Application Number	10/701,265	
INFO	ORMATION	DISCLOS	SURE	Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
Sheet	11	of	44	Attorney Docket Number	ISIS-5300

		U. S.	PATENT DOC	UMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	261	5,914,396 A	06-22-1999	Cook et al.	
	262	5,936,080 A	08-10-1999	Stec et al.	
	263	5,945,521 A	08-31-1999	Just et al.	
	264	5,965,720 A	10-12-1999	Gryaznov et al.	
	265	5,965,721 A	10-12-1999	Cook et al.	
	266	5,969,116 A	10-19-1999	Martin	
	267	5,969,118 A	10-19-1999	Sanghvi et al.	
	268	5,986,083 A	11-16-1999	Dwyer et al.	
	269	5,998,588 A	12-07-1999	Hoffman et al.	
	270	6,001,841	12-14-1999	Cook et al.	
	271	6,005,087	12-21-1999	Cook et al.	
	272	6,005,094 A	12-21-1999	Simon et al.	
	273	6,005,096	12-21-1999	Matteucci et al.	
	274	6,007,992	12-28-1999	Lin et al.	
	275	6,013,785 A	01-11-2000	Bruice et al.	
	276	6,015,886 A	01-18-2000	Dale et al.	
	277	6,020,475	02-01-2000	Capaldi et al.	
	278	6,025,140	02-15-2000	Langel et al.	
	279	6,028,183	02-22-2000	Lin et al.	
	280	6,028,188 A	02-22-2000	Arnold, Jr. et al.	
	281	6,043,060	03-28-2000	Imanishi	
	282	6,043,352 A	03-28-2000	Manoharan et al.	
	283	6,051,699	04-18-2000	Ravikumar	
	284	6,087,484 A	07-11-2000	Goodchild	
	285	6,096,875 A	08-01-2000	Khan et al.	
	286	6,111,085 A	08-29-2000	Cook et al.	

	U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	287	6,121,437	09-19-2000	Guzaev et al.					
	288	6,127,346	10-03-2000	Peyman et al.					
	289	6,127,533 A	10-03-2000	Cook et al.					
	290	6,147,200	11-14-2000	Manoharan et al.					
	291	6,153,737 A	11-28-2000	Manoharan et al.					
	292	6,166,188 A	12-26-2000	Cook et al.					
	293	6,169,177	01-02-2001	Manoharan					
	294	6,172,208 B1	01-09-2001	Cook					
	295	6,172,209	01-09-2001	Manoharan et al.					
	296	6,172,216 B1	01-09-2001	Bennett et al.					
	297	6,207,646	03-27-2001	Krieg et al.					
	298	6,222,025 B1	04-24-2001	Cook et al.					
	299	6,227,982 B1	05-08-2001	Wurster					
	300	6,239,265 B1	05-29-2001	Cook					
	301	6,239,272 B1	05-29-2001	Beigelman et al.					
	302	6,262,241 B1	07-17-2001	Cook et al.					
	303	6,268,490	07-31-2001	Imanishi et al.					
	304	6,271,358 B1	08-07-2001	Manoharan et al.					
	305	6,277,634	08-21-2001	McCall et al.					
	306	6,277,967 B1	08-21-2001	Manoharan					
	307	6,281,201 B1	08-28-2001	Suhadolnik et al.					
	308	6,284,538 B1	09-04-2001	Monia et al.					
	309	6,287,860	09-11-2001	Monia et al.					
	310	6,300,319 B1	10-09-2001	Manoharan					
	311	6,307,040 B1	10-23-2001	Cook et al.					
	312	6,326,358 B1	12-04-2001	Manoharan					

	Substitute for 1449/PTO		Complete if Known		
Substitute for			Application Number	10/701,265	
	PRMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
Sheet	13	of	44	Attorney Docket Number	ISIS-5300

		U. S.	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	313	6,326,478	12-04-2001	Cheruvallath et al.	
	314	6,331,617 B1	12-18-2001	Weeks et al.	
	315	6,335,432 B1	01-01-2002	Segev	
	316	6,335,434 B1	01-01-2002	Guzaev et al.	
	317	6,335,437 B1	01-01-2002	Manoharan et al.	
	318	6,344,436 B1	02-05-2002	Smith et al.	
	319	6,358,931 B1	03-19-2002	Cook et al.	
	320	6,365,379 B1	04-02-2002	Lima et al.	
	321	6,395,437 B1	05-28-2002	Wollesen	
	322	6,395,492 B1	05-28-2002	Manoharan et al.	
	323	6,410,702 B1	06-25-2002	Swaminathan et al.	
	324	6,414,127	07-02-2002	Lin et al.	
	325	6,420,549 B1	07-16-2002	Cook et al.	
	326	6,426,220	07-30-2002	Bennett et al.	
	327	6,440,943 B1	08-27-2002	Cook et al.	
	328	6,444,806 B1	09-03-2002	Veerapanani et al.	
	329	6,465,628	10-15-2002	Ravikumar et al.	
	330	6,476,205 B1	11-05-2002	Buhr et al.	
	331	6,486,308 B2	11-26-2002	Kutyavin et al.	
	332	6,525,031 B2	02-25-2003	Manoharan	
	333	6,528,631 B1	03-04-2003	Cook et al.	
	334	6,531,584 B1	03-11-2003	Cook et al.	
	335	6,534,639 B1	03-18-2003	Manoharan et al.	
	336	6,559,279 B1	05-06-2003	Manoharan et al.	
	337	6,593,466	07-15-2003	Manoharan et al.	
	338	6,656,730	12-02-2003	Manoharan	

	Substitute for 1449/PTO		Compl	ete if Known	
Substitute for	1449/PTO			Application Number	10/701,265
	PRMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	14	of	44	Attorney Docket Number	ISIS-5300
•			1	ı	1

	U. S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	339	6,670,461	12-30-2003	Wengel et al.					
	340	6,673,611 B2	01-06-2004	Thompson et al.					
	341	6,683,167 B2	01-27-2004	Metelev et al.					
	342	6,794,499	09-21-2004	Wengel et al.					
	343	6,887,906	05-03-2005	Teng et al.					
	344	RE34,069	09-15-1992	Koster et al.					

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials	Cite No	Foreign Patent Document Country Code- Number -Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	345	CA 2,017,369 C	01-23-2001	Roche Diagnostics GmbH		
	346	DE 10100588 A1	07-18-2002	Ribopharma		
	347	DE 3915432 A1	11-15-1990	Klockner-Humboldt-Deutz AG		
	348	DE 4110085 A1	01-10-1992	Boehringer Ingelheim Int'l. GmbH		
	349	EP 0260032 A2	03-16-1988	Ajinmoto Co., Inc.		
	350	EP 0269574 A2	06-01-1988	Nippon Zoki Pharmaceutical Co. Ltd.		
	351	EP 0287313 A2	10-19-1988	Marquez		
	352	EP 0339330 A2	11-02-1989	Spradau, Hans F.W.		
	353	EP 0417999 A1	03-20-1991	The Wellcome Foundation Limited		
	354	EP 1389637 A1	02-18-2004	Atugen AG		
	355	WO 00/08044 A1	02-17-2000	Isis Pharmaceuticals, Inc.		
	356	WO 00/76554 A1	12-21-2000	Isis Pharmaceuticals, Inc.		
	357	WO 01/049687 A2	07-12-2001	K.U. Leuven Research & Development		
	358	WO 02/36743 A2	05-10-2002	Isis Pharmaceuticals, Inc.		
	359	WO 02/38578 A1	05-16-2002	Chattopadhyaya		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No	Foreign Patent Document Country Code- Number -Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T		
	360	WO 03/004602 A2	01-16-2003	Isis Pharmaceuticals, Inc.				
	361	WO 03/070918 A2	08-28-2003	Ribozyme Pharm Inc.				
	362	WO 2004/015107 A2	02-19-2004	Atugen AG				
	363	WO 2004/041889 A2	05-21-2004	Isis Pharm.				
	364	WO 2004/043977 A2	05-27-2004	Isis Pharm.				
	365	WO 2004/043978 A2	05-27-2004	Isis Pharm.				
	366	WO 2004/043979 A2	05-27-2004	Isis Pharm.				
	367	WO 2004/044133 A2	05-27-2004	Isis Pharm.				
	368	WO 2004/044136 A2	05-27-2004	Isis Pharm.				
	369	WO 2004/044138 A2	05-27-2004	Isis Pharm.				
	370	WO 2004/044139 A2	05-27-2004	Isis Pharmaceuticals Inc.				
	371	WO 2004/044140 A2	05-27-2004	Isis Pharm.				
	372	WO 2004/083430 A2	09-30-2004	Elmen et al.				
	373	WO 2004/097049 A1	11-11-2004	Isis Pharmaceuticals, Inc.				
	374	WO 2004/113496 A2	12-29-2004	Isis Pharm.				
	375	WO 2005/027962 A2	03-31-2005	Isis Pharm.				
	376	WO 89/12060 A1	12-14-1989	Benner				
	377	WO 90/15814 A1	12-27-1990	Meiogenics, Inc.				
	378	WO 91/06556 A1	05-16-1991	Gilead Sciences, Inc.				
	379	WO 91/10671 A1	07-25-1991	Isis Pharmaceuticals, Inc.				
	380	WO 91/15499 A1	10-17-1991	Europaisches Laboratorium Fur Molekularbiologie				
	381	WO 92/02258 A1	02-20-1992	Isis Pharmaceuticals, Inc.				
	382	WO 92/03452 A1	03-05-1992	Isis Pharmaceuticals, Inc.				
	383	WO 92/03568 A1	03-05-1992	Isis Pharmaceuticals, Inc.				
	384	WO 93/07883 A1	04-29-1993	Isis Pharmaceuticals, Inc.				

	4.4.40/DTO			Complete if Known		
Substitute for	1449/PTO			Application Number	10/701,265	
	PRMATION			Filing Date	11-04-2003	
STA	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	16	of	44	Attorney Docket Number	ISIS-5300	
•	'	•	•	ı	1	

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials	Cite No	Foreign Patent Document Country Code- Number -Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	385	WO 93/24510 A1	12-09-1993	Centre National de la Recherche		
	386	WO 94/01550 A1	01-20-1994	Hybridon, Inc.		
	387	WO 94/26764 A1	11-24-1994	Centre National de la Recherche		
	388	WO 96/11205 A1	04-18-1996	Isis Pharmaceuticals, Inc.		
	389	WO 97/26270 A2	07-24-1997	Ribozyme Pharm.		
	390	WO 97/30064 A1	08-21-1997	Stichting REGA		
	391	WO 97/46570 A1	12-11-1997	Isis Pharmaceuticals, Inc.		
	392	WO 98/16550 A1	04-23-1998	Isis Innovation Limited		
	393	WO 98/39352 A1	09-11-1998	Imanishi		
	394	WO 98/52614 A2	11-26-1998	The Board of Trustees of the Leland Stanford Junior Univ.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue Number(s), publisher, city and/or country where published.	Т
	395	Abe, A., et al., "Conformational energies and the random-coil dimensions and dipole moments of the polyoxides CH3O[CH2)yO]xCH3," J. Am. Chem. Soc., 1976, 98(21), 6468-6476	
	396	Afonina, I. et al., "Sequence-specific arrest of primer extension on single-stranded DNA by an oligonucleotide-minor groove binder conjugate," Proc. Natl. Acad. Sci. USA (1996) 93:3199-3204.	
	397	Agarwal, et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus" Proc. Natl. Acad. Sci. USA, 1988, 85, 7079-7083	
	398	Agarwal, et al., "Synthesis and Enzymatic Properties of Deoxyribooligonucleotides Containing Methyl and Phenylphosphonate Linkages", Nucleic Acid Research 1979, 6, 3009-3024	
	399	Agrawal, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?," Molecular Med. Today, Vol. 6(2), pages 72-81 (2000)	

	4.4.4.0/DTO			Complete if Known		
Substitute for	1449/PTO			Application Number	10/701,265	
	ORMATION			Filing Date	11-04-2003	
STA	TEMENT B	BY APPLIC	ANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	17	of	44	Attorney Docket Number	ISIS-5300	
•		'		'	•	

	NON PATENT LITERATURE DOCUMENTS
400	Agris, et al., "Inhibition of Vesicular Stomatitis Virus Protein Synthesis and Infection by Sequence-Specific Oligodeoxyribonucleoside Methylphosphonates", Biochemistry 1986, 25, 6268-6275
401	Allerson, C.R. et al., Abstract of the 227th ACS National Meeting, Anaheim, CA, March 28-April 1, 2004
402	Allerson, C.R. et al., "Fully 2'-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA," J. Med. Chem., 2005, 48, 901-904
403	Altmann, KH. et al., "Second generation antisense oligonucleotides - inhibition of PKC-alpha and c-RAF kinase expression by chimeric oligonucleotides incorporating 6' -substituted carbocyclic nucleosides and 2' -O-ethylene glycol substituted ribonucleosides," Nucleosides & Nucleotides, 1997, 16(7-9), 917-926
404	Altmann, KH., et al., "Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals," Chimia, 1996, 50, 168-176
405	Altmann, K.H., et al., "Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors," Biochem. Soc. Trans., 1996, 24, 630-637
406	Altschul, S.F. et al., "Basic Local Alignment Search Tool," J. Mol. Biol., 1990, 215, 403-410
407	Ambros, V. et al., "A uniform system for MicroRNA annotation," RNA (2003) 9: 277-279
408	Ambros, V. et al., "MicroRNAs and Other Tiny Endogenous RNAs in C. elegans, "Curr Biol. (2003) 13: 807-818
409	Ambros, V. et al., "MicroRNAs: Tiny Regulators with Great Potential," Cell (2001) 107: 823-826
410	Antopolsky, M. et al., "Peptide-Oligonucleotide Phosphorothioate Conjugates with Membrane Translocation and Nuclear Localization Properties," Bioconjuxate Chem. (1999) 10(4):598-606.
411	Arar, K. et al., "Synthesis and Antiviral Activity of Peptide-Oligonucleotide Conjugates Prepared by Using Na-(Bromoaceytl)peptides," Bioconjugate Chem. (1995) 6(5):573-577.
412	Arnott, S., et al., "Optimised parameters for A-DNA and B-DNA," Biochem. & Biophys. Res. Comm., 1972, 47(6), 1504-1510
413	Asseline, U. et al., "Nucleic acid-binding molecules with high affinity and base sequence specificity: Intercalating agents covalently linked to oligodeoxynucleotides," Proc. Natl. Acad. Sci USA (1984) 81: 3297-3301

	4.4.4.0./DTO			Comp	lete if Known	
Substitute for	1449/PTO			Application Number	10/701,265	
INFC	RMATION	I DISCLO	SURE	Filing Date	11-04-2003	
STA	TEMENT E	3Y APPLI	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessar	y)	Examiner Name	Jennifer S. Pitrak	
Sheet	18	of	44	Attorney Docket Number	ISIS-5300	
	1	Ī	1	ı		

	NON PATENT LITERATURE DOCUMENTS	
414	Astriab-Fisher et al., "Conjugates of antisense olgonucleotides with the TAT and antennapedia cell-penetrating peptides: effects on cellular update, binding to target sequences and biologic actions," Pharmaceutical Research (2002) 19(6): 744-754	
415	Astriab-Fisher, A. et al., "Antisense Inhibition of P-glycoprotein Expression Using Peptide-Oligonucleotide Conjugates," Biochem. Pharmacol. (2000) 60, 83-90.	
416	Baker, B. F. et al., "Oligonucleotide-europium complex conjugate designed to cleave the 5' cap structure of the ICAM-I transcript potentiates antisense activity in cells," Nucleic Acids Res. (1999) 27(6):1547-1551.	
417	Baker, B.F., et al., "2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells," J. Biol. Chem., 1997, 272(18), 11944-12000	
418	Bartel, B. et al., "MicroRNAs: At the Root of Plant Development," Plant Physiol. (2003) 132: 709-717	
419	Bayer, E. et al., "A New Support for Polypeptide Synthesis in Columns," Tetrahedron Letters, 1970, 51, 4503-4505	
420	Beaucage et al. "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives", (1993) Tetrahedron 49(10):1925-1963	
421	Beaucage S. and Iyer, R., "The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications", Tetrahedron, 1993, 49, 6123-6194	
422	Beaucage, S.L. et al., "Deoxynucleoside Phosphoramidites-A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,", Tetrahedron Letts., 1981, 22, 1859-1862	
423	Biggadike, et al., "Short convergent route to homochiral carbocylic 2'-deoxynucleosides and carbocyclic robonucleosides", J. Chem. Soc. Chem. Commun. 1987, 1083-1084	
424	Bollig, F. et a]., "Affinity purification of ARE-binding proteins identifies poly(A)-binding protein 1 as a potential substrate in MK2-induced mRNA stabilization," Biochem. Bioophys. Res. Commun. (2003) 301: 665-670	
425	Bongartz, JP. et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," Nucleic Acids Res. (1994) 22(22):4681-4688.	
426	Bonora, G. M. et al., "Antisense activity of an anti-HIV oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycols," Farmaco (1998) 53:634-637.	
427	Bonora, G. M. et al., "Biological Properties of Antisense Oligonucleotides Conjugated to - Different High-Molecular Mass Poly(Ethy1en Glycols)," Nucleosides Nucleotides (1999) 18(6&7):1723-1725	

			Сотр	lete if Known
449/PTO			Application Number	10/701,265
RMATION	DISCLOS	SURE	Filing Date 11-04-2003	
STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
			Art Unit	1635
(use as many she	ets as necessary,)	Examiner Name	Jennifer S. Pitrak
19	of	44	Attorney Docket Number	ISIS-5300
	NON F	ATENT LIT	ERATURE DOCUMENTS	
Bonora, G.M., et al., "A liquid-phase process suitable for large-scale synthesis of phosphorothioate oligonucleotides," Organic Process Res. & Develop., 2000, 225-231				
Borer, et al., "Stability of ribonucleic acid double-stranded helices," J. Mol. Biol., 1974, 86, 843-853				
	(use as many sheet 19 Bonora, G. phosphoro	RMATION DISCLOSTEMENT BY APPLICATION OF TEMENT BY APPLICATION OF THE PROPERTY	RMATION DISCLOSURE FEMENT BY APPLICANT (use as many sheets as necessary) 19 of 44 NON PATENT LIT B Bonora, G.M., et al., "A liquid-phase phosphorothioate oligonucleotides," of the phosphorothioate oligonucleotides and the phosphorothioate oligonucleotides are phosphorothioate oligonucleotides." Of the phosphorothioate oligonucleotides are phosphorothioate oligonucleotides.	Application Number Filing Date First Named Inventor Art Unit Examiner Name 19 of 44 Attorney Docket Number NON PATENT LITERATURE DOCUMENTS Bonora, G.M., et al., "A liquid-phase process suitable for large-scal phosphorothioate oligonucleotides," Organic Process Res. & Deve

	NON PATENT LITERATURE DOCUMENTS
428	Bonora, G.M., et al., "A liquid-phase process suitable for large-scale synthesis of phosphorothioate oligonucleotides," Organic Process Res. & Develop., 2000, 225-231
429	Borer, et al., "Stability of ribonucleic acid double-stranded helices," J. Mol. Biol., 1974, 86, 843-853
430	Braasch et al., "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design," Nucleic Acids Research, 2002, 30, 5160-5167
431	Braasch, D.A. et al., "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA," Chem Biol, 2001, 8, 1-7
432	Braasch, D.A. et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," Biochemistry, 2003, 42, 7967-7975
433	Braasch, D.A., et al., "Novel antisense and peptide nucleic acid strategies for controlling gene expression," Biochemistry, April 9, 2002, 41(14), 4503-4510
434	Branda et al., "Amplification of antibody production by phosphorothioate oligodeoxynucleotides," J. Lab. Clin. Med., 1996, 128(3), 329-338
435	Branden, L. J. et al., "A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA," Nature Biotech (1999) 17:784-787.
436	Brazma, A., et al., "Gene expression data analysis," FEBS Lett., 2000, 480, 17-24
437	Brill, et al., "Synthesis of Oligodeoxynucleoside Phosphorodithioates Via Thioamidites", J. Am. Chem. Soc. 1989, 111, 2321-2322
438	Brown-Driver et al., "Inhibition of Translation of Hepatitis C Virus RNA by 2'-Modified Antisense Oligonucleotides," Antisense Nucleic Acid Drug Dev. (1999) 9(2): 145-154
439	Buhr, C.A. et al., "Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza-2'-deoxyguanosine and 7-deaza-2'-deoxyadenosine," Nucleic Acids Research, 1996, 24(15), 2974-2980
440	Butke, et al., "Facile synthesis of 2'amino-2deoxynucleoside from the corresponding arabino derivative," Nucleic Acid Chemistry, 1986, Part Three, 149-152
441	Butler, M. et al., "Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice," Diabetes, 2002, 51, 1028-1034
442	Caplen et al., "dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference," GENE (2000) 252: 95-105

	10/DT0		Сотр	lete if Known			
ubstitute for 1449/PTO			Application Number	10/701,265			
INFOR	MATION DISCLOS	SURE	Filing Date	11-04-2003			
STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker			
			Art Unit	1635			
(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak			
Sheet	20 of	44	Attorney Docket Number	ISIS-5300			
	NON P	ATENT LITI	ERATURE DOCUMENTS				
443	Carulli, J.P., et al., "High throughput analysis of differential gene expression," J. Cellular Biochem. Suppl., 1998, 30(31), 286-296						
444	Caruthers M "Synthesis	caruthers M. "Synthesis of Oligonucleotides and Oligonucleotide Analogues", in					

	NON PATENT LITERATURE DOCUMENTS
443	Carulli, J.P., et al., "High throughput analysis of differential gene expression," J. Cellular Biochem. Suppl., 1998, 30(31), 286-296
444	Caruthers, M., "Synthesis of Oligonucleotides and Oligonucleotide Analogues", in "Oligonucleotides. Antisense Inhibitors of Gene Expression.", J.S. Cohen, Ed., CRC Press, Inc., 7-24, (1989)
445	Castle, et al., "Imidazo[4, 5-D]pyridazines. I. Synthesis of 4,7-disubstituted derivatives", Journal of Organic Chemistry, 1958, 23, 1534-1538
446	Cazalla, D. et al., "Nuclear Export and Retention Signals in the RS Domain of SR Proteins," Mol. Cell. Biol. (2002) 22(19):6871-6882.
447	Cazenave, C. et al., "Enzymatic amplification of translation inhibition of rabbit β-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents", Nucl. Acids Res., 1987, 15, 4717-4736
448	Celis, J.E., et al., "Gene expression profiling: monitoring transcription and translation production using DNA microarrays and proteomics," FEBS Lett., 2000, 480, 2-16
449	Cerutti, H., "RNA interference: traveling in the cell and gaining functions?" Trends in Genetics (2003) 19(1): 39-46
450	Chaloin, L. et al., "Design of Carrier Peptide-Oligonucleotide Conjugates with Rapid Membrane Translocation and Nuclear Localization Properties," Biochem. Biophys. Res. Commun. (1998) 243:601-608
451	Chaput, J.C., et al., "DNA polymerase-mediated DNA synthesis on a TNA template," J. Am. Chem. Soc., 2003, 125, 856-857
452	Chen and Wu, "Studies on Fluoroalkylation and Fluroalkoxylation. Part 33. Direct Trifluoromethylation of Aryl Halides with Fluorosulphonyldifluoromethyl lodide in the Presence of Copper: an Electron Transfer Induced Process," J. Chem. Soc., Perkin Transactions, 1989, 1, 2385-2387.
453	Chiang et al., "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms," J. Biol. Chem., 1991, 266, 18162-18171
454	Chirila, T.V. et al., "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides," Biomaterials, Vol. 23(2), pages 321-342 (2002)
455	Chiu et al., "siRNA function in RNAi: a chemical modification analysis," RNA, 2003, 9, 1034-1048
456	Chladek, et al., "Facile Synthesis of 2'Amino-2'Deoxyadenosine," J. Carbohydtrates, Necleosides & Nucleotides, 1980, 7, 63-75.

Substitute for 1449/PTO		Complete if Known		
1449/PTO			Application Number	10/701,265
			Filing Date	11-04-2003
STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
			Art Unit	1635
(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
21	of	44	Attorney Docket Number	ISIS-5300
	RMATION FEMENT E	RMATION DISCLOS TEMENT BY APPLIC	RMATION DISCLOSURE FEMENT BY APPLICANT (use as many sheets as necessary)	Application Number RMATION DISCLOSURE Filing Date First Named Inventor Art Unit (use as many sheets as necessary) Examiner Name

	NON PATENT LITERATURE DOCUMENTS	
457	Choung, S. et al., "Chemical modification of siRNAs to improve serum stability without loss of efficacy," Biochemical and Biophysical Research Communications, 2006, 342, 919-927	
458	Christofferson et al., "Ribozymes as human therapeutic agents", J. Med. Chem., 1995, 38(12), 2023-2037	
459	Chun-Nam Lok et al., "Potent gene-specific inhibitory properties of mixed backbone antisense oligonucleotides comprised of 2' -deoxy-2' -fluoro-D-arabinose and 2' -deoxyribose nucleotides," Biochemistry, 2002, 41, 3457-3467	
460	Cohen, G. L. et al., "Sequence Dependent Binding of cis-Dichlorodiamrnineplatinum(II) to DNA," J. Am. Chem. Soc. (1980) 102(7), 2487-2488.	
461	Constant et al., "Heterodimeric Molecules Including Nucleic Acid Bases and 9-Aminoacridine Spectroscopic Studies, Conformations, and Interactions with DNA", Biochemistry, 1988, 27, 3997-4003	
462	Conte, M.R., et al., "Conformational properties and thermodynamics of the RNA duplex r(CGCAAAUUUGCG)2: comparison with the DNA analogue d(CGCAAATTTGCG)2," Nucleic Acids Res., 1997, 25(13), 2627-2634	
463	Copy of PCT International Search Report dated January 24, 2005 (PCTUS03/35087)	
464	Corey, D. R. et al., "Generation of a Hybrid Sequence-Specific Single-Stranded Deoxyribonuclease," Science (1987) 238:1401-1403.	
465	Corey, D. R. et al., "Sequence-Selective Hydrolysis of Duplex DNA by an Oligonucleotide-Directed Nuclease," J. Am. Chem. Soc. (1989) 111(22):8523-8525.	
466	Corey, D. R., "48000-fold Acceleration of Hybridization by Chemically Modified Oligonucleotides," J. Am. Chem. Soc. (1995) 117(36):9373-9374.	
467	Cornell, W. D. et al., "A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules," J. Am. Chem. Soc., 1995, 117, 5179-5197	
468	Cossum, P.A. et al., "Disposition of the 14C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats," J. Pharmacol. Exp. Ther., 1993, 267(3), 1181-1190	
469	Couzin, J., "Small TNAs Make Big Splash," Science (2002) 298: 2296-2297	
470	Crawford, J.M., "Role of Vesicle-Mediated Transport Pathways in Hepatocellular Bile Secretion," Semin. Liver Dis., 1996, 16(2), 169-189	
471	Crooke, S.T., Antisense Research & Application, Chapter 1, Pages 1-50, Publ. Springer-Verlag, Ed. S.T. Crooke (1998).	

Substitute for 1449/PTO		Complete if Known			
Substitute for '	1449/P1O			Application Number	10/701,265
	RMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
(use as many sheets as necessary)				Examiner Name	Jennifer S. Pitrak
Sheet	22	of	44	Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
47.	Cummins, L.L. et al., "Characterization of fully 2'modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity," Nucleic Acids Research, 1995, 23(11), 2019-2024
47.	Dahl, B.H. et al., "A Highly Reactive, Odourless Substitute for Thiphenol/Triethylmaine as a Deprotection Reagent in the Synthesis of Oligonucleotides and their Analogues," Acta Chem. Scand., 1990, 44, 639-641
47	Damha, et al., "Solution and solid phase chemical synthesis of arabinonucleotides", Can J. Chem., 1989, 831-839
47	Dande, P. et al., Abstract from The 227th ACS National Meeting, Anaheim, CA, March 28-April 1, 2004
47	De las Heras, et al., "3'-C-Cyano-3'-Deoxythymidine," Tetrahedron Letters, 1988, 29, 941-944
47	Dellinger, D.J. et al., "Solid-Phase Chemical Synthesis of Phosphonoacetate and Thiophosphonoacetate Oligodexynucleotides," J. Am. Chem. Soc., 2003, 125(4), 940-950
479	Denny, W.A., "DNA-intercalating ligands as anti-cancer drugs: prospects for future design," Anti-Cancer Drug Design, 1989, 4, 241-263
479	Dignam, et al., "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei," Nucleic Acids Res., 1983, 11, 1475-1489
48	Divakar, et al., "Approaches to the Synthesis of 2'-Thio Analogues of Pyrimidine Ribosides", J. Chem. Soc., Perkins Trans., I, 1990, 969-974
48	Divakar, et al., "Reaction Between 2,2'-Anhydro-1-β-D-arrabinofuranosyluracil and Thiolate lons", J. Chem. Soc., Perkins Trans. I, 1982, 1625-1628
48.	Dreyer, et al., "Sequence-specific cleavage of single-stranded DNA: Oligodeoxynucleotide-EDTA-Fe(II)", Proc. Natl. Acad. Sci. USA, 1985, 82, 968-972
48.	Duff, R. J. et al., "[17] Intrabody Tissue-Specific Delivery of Antisense Conjugates in Animals: Ligand-Linker-Antisense Oligomer Conjugates," Methods Enzymol. (2000) 313:297-321.
48	Eckstein, et al., "Polynucleotides Containing 2'Chloro-2'Deoxyribose", Biochemistry, 1972, 11, 4336-4344
48	Eddy, S.R., "Non-Coding RNA Genes and the Modern RNA World," Nature Rev. Genetics (2001) 2: 919-929
48	Efimov, V. A. et al., "Synthesis of Polyethylene Glycol - Oligonucleotide Conjugates," Bioorg. Khim. (1993) 19(8):800-804.

Substitute for 1449/PTO		Complete if Known			
Substitute for	1449/P1O			Application Number	10/701,265
	RMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
Sheet	23	of	44	Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
487	Egli, M. et al., "RNA Hydration: A Detailed Look," Biochemistry, 1996, 35, 8489-8494
488	Elayadi, A.N. et al., "Application of PNA and LNA oligomers to chemotherapy," Curr. Opin. Investig. Drugs, 2001, 2(4), 558-561
489	Elmén, J. et al., "Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality," Nucleic Acids Res. 2005, 33(1), 439-447
490	EP Supplementary Search Report for EP 03716922 dated May 12, 2006
491	Faria, M. et al., "Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo," Nature Biotech., 2001, 19, 40-44
492	Fazakerley, G.V., et al., "A→Z transition in the synthetic hexanucleotide (dCdGfl)3," FEBS, 1985, 182(2), 365-369
493	Fedoroff, O.Y. et al., "Structure of a DNA:RNA Hybrid Duplex," J. Mol. Biol., 1993, 233, 509-523
494	Fieser, L. et al., Fieser and Fieser's Reagents for Organic Synthesis (1994), John Wiley & Sons, New York
495	Fire et al., "RNA-triggered gene silencing," TIG (1999) 15(9): 358-363
496	Firestone, R. A., "Low-Density Lipoprotein as a Vehicle for Targeting Antitumor Compounds to Cancer Cells," Bioconjugate Chern. (1994) 105-113.
497	Flanagan, W. M. et al., "A cytosine analog that confers enhanced potency to antisense oligonucleotides," Proc. Natl. Acad. Sci. USA, Mar. 1999, 96, 3513-3518
498	Flanagan, W.M. et al., "Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide," Nature Biotechnol. (1999) 17(1): 48-52
499	Fluiter, K. et al., "In vivo tumor growth inhibition and biodistribution studies of locked nucleic acids (LNA) antisense oligonucleotides," Nucleic Acids Res., 2003, 31(3), 953-962
500	Fox, et al., "Nucleosides. XVIII. Synthesis of 2'-Fluorothymidine, 2'-Flurodeoxyuridine, and Other 2'-Halogeno-2'-Deoxy Nucleosides 12", J Org. Chem., 1964, 29, 558-564
501	Francis, A.W. et al., "Probing the Requirements for Recognition and Catalysis in Fpg and MutY with Nonpolar Adenine Isosteres," J. Am. Chem. Soc. (2003) 125(52): 16235-16242
502	Fraser, A., et al., "Synthesis and conformational properties of 2'-deoxy-2'-methylthiopyrimidine and -purine nucleosides:potential antisense applications," J. Heterocycl. Chem., 1993, 30, 1277-1287

Substitute for 1449/PTO		Comp	lete if Known
		Application Number	10/701,265
INFORMATION DISCLOS	URE	Filing Date	11-04-2003
STATEMENT BY APPLICANT		First Named Inventor	Brenda F. Baker
		Art Unit	1635
(use as many sheets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet 24 of	44	Attorney Docket Number	ISIS-5300
, , ,		1	1
NON P/	ATENT LIT	ERATURE DOCUMENTS	

	NON PATENT LITERATURE DOCUMENTS
503	Fraser, A.G. et al., "Functional genomic analysis of C. elegans chromosome 1 by systemic RNA interference," Nature, 2000, 408, 325-330
504	Freier, S. M. et al., "The ups and downs of nucleic acid duplex stability: structure–stability studies on chemically-modified DNA:RNA duplexes," Nucleic Acids Research, 1997, 25(22), 4429-4443
505	Freskos, "Synthesis of 2'Deoxypyrimidine Nucleosides Via Copper (I) Iodine Catalysis," Nucleosides & Nucleotides, 1989, 8, 1075, 1076
506	Frieden, M. et al., 'Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA," Nucleic Acids Res., 2003, 31(21), 6365-6372
507	Fromageot, H.P.M. et al., "The Synthesis of Oligonucleotides," Tetrahedron, 1967, 23, 2315-2331
508	Fuchs, B. et al., "Identification of Differentially Expressed Genes by Mutually Subtracted RNA Fingerprinting," Anal. Biochem., 2000, 286, 91-98
509	Gaffney, et al., "A New Strategy for the Protection of eoxyguanosine During Oligonucleotide Synthesis," Tetrahedron Letters, 1982, 23, 2257-2260
510	Gait, M.J. et al., "Application of chemically synthesized RNA," RNA: Protein Interactions (1998) Smith (ed.), pp. 1-36
511	Gait, M.J., "Oligoribonucleotides, Antisense Research and Applications, 1993, Crooke, S.T. and Lebleu, B. (eds.), CRC Press, Boca Raton, pp. 289-301
512	Gallo, M. et al., "2'-C-Methyluridine phosphoramidite: a new building block for the preparation of RNA analogues carrying the 2'-hydroxyl group," Tetrahedron, 2001, 57(27), 5707-5713
513	Gao, J. et al., "Expanded-Size Bases in Naturally Sized DNA: Evaluation of Steric Effects in Watson-Crick Pairing," J. Am. Chem. Soc. (2004) 126(38): 11826-11831
514	Geary, R.S. et al., "Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats," J. Pharmacol. Exp. Therap., 1998, 296(3), 890-897
515	Going, J.J., et al., "Molecular pathology and future developments," Eur. J. Cancer, 1999, 35(14), 1895-1904
516	Gonzalez, C. et al., "Structure and Dynamics of a DNA-RNA Hybrid Duplex with a Chral Phosphorothioate Moiety: NMR and Molecular Dynamics with Conventional and Time-Averaged Restraints," Biochemistry, 1995, 34, 4969-4982
517	Gorlach, M. et al., "The rnRNA Poly(A)-Binding Protein: Localization, Abundance, and RNABinding Specificity," Exp. Cells Res. (1994) 211:400-407

Substitute for 1449/PTO		Complete if Known		
1449/P1O			Application Number	10/701,265
-			Filing Date	11-04-2003
STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
			Art Unit	1635
(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
25	of	44	Attorney Docket Number	ISIS-5300
)	RMATION FEMENT B	RMATION DISCLOS TEMENT BY APPLIC	RMATION DISCLOSURE FEMENT BY APPLICANT (use as many sheets as necessary)	Application Number RMATION DISCLOSURE Filing Date First Named Inventor Art Unit (use as many sheets as necessary) Examiner Name

	NON PATENT LITERATURE DOCUMENTS
518	Graham, et al., "Tritium Labeling of Antisense Oligonucleotides by Exchange with Tritiated Water," Nucleic Acids. Res., 1993, 16, 3737-3743
519	Graham, M.J. et al., "In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration," J. Pharmacol. Exp. Therap., 1998, 286(1), 447-458
520	Gravert, D.J., et al., "Organic synthesis on soluble polymer supports," Chem. Rev., 1997, 97, 489-509
521	Griffey, R.H. et al., "2'-O-Aminopropyl Ribonucleotides: A Zwitterionic Modification that Enhances the Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides," J. Med. Chem., 1996, 39(26), 5100-5109
522	Griffin, B.E. et al., "The Synthesis of Oligoribonucleotides," Tetrahedron, 1967, 23, 2301-2313
523	Grishok, A. et al., "Genetic Requirements for Inheritance of RNAi in C. elegans," Science, 2000, 287, 2494-2497
524	Grünweller, A. et al., "Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA," Nucleic Acids Research, 2003, 31(12), 3185-3193
525	Gryaznov, S. et al., "Oligodeoxynucleotide N3'P5' Phosphoramidates: Synthesis and Hybridization Properties," J. Am. Chem. Soc., 1994, 116(7), 3143-3144
526	Guckian, K.M. et al., "Structure and Base Pairing Properties of a Replicable Nonpolar Isostere for Deoxyadenosine," J Org Chem (1998) 63(26);9652-9656
527	Guillerm, D. et al., "Synthesis of 4'-fluoroadenosine as an inhibitor of S-adenosyl-L-homocysteine hydrolase," Bioorganic & Medicinal Chemistry Letters, 1995, 5(14), 1455-1460
528	Guschlbauer, et al., "Nucleoside conformation is Determined by the Electronegativity of the Sugar Substituent," Nucleic Acids Res., 1980, 8, 1421-1433
529	Guschlbauer, W. et al., "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic characterization and interaction with poly-inosinic acid," Nucleic Acid Research, 1977, 4(6),1933-1943
530	Guschlbauer, W., et al., "Use of 2'-deoxy-2'-fluoro-necleosides in the study of polynucleotide conformation: a progress report," Nucleic Acid Research Symposium Series, 1982, 11,113-116
531	Gutierrez, A.J. et al., "Antisense Gene Inhibition by C-5 Substituted Deoxyuridine-Containing Oligodeoxynucleotides," Biochemistry, 1997, 36(4), 743-748

Cubatituta for 1110/DTO		Complete if Known			
Substitute for	e for 1449/PTO		Application Number	10/701,265	
	RMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
Sheet	eet 26 of 44			Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
532	Guzaev, A. et al., "Conjugation of Oligonucleotides Via an Electrophilic Tether: N-Chloroacetarnidohexyl Phosphoramidite Reagent," Bioorg. Med. Chem. lett . (1998) 8:3671-3676.
533	Hakimelahi, G.H. et al., "High Yield Selective 3'-Silylation of Ribonucleosides," Tetrahedron Lett., 1981, 22(52), 5243-5246
534	Hall, J. et al., "Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides," Chem. Biol. (1994) 1(3):185-190.
535	Hamada et al., "Effects on RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3'Ends of siRNAs," Antisense and Nucleic Acid Drug Development (2002) 12:301-309
536	Hamilton et al., "A species of small antisense RNA in posttranscriptional gene silencing in plants," Science (1999) 286 (5441): 950-952
537	Hansske, et al., "2'and 3'-ketonucleosides and their arabino and XYLO reduction products," Tetrahedron, 1984, 40, 125-135
538	Hariton-Gazal, E. et al., "Targeting of Nonkaryophilic Cell-Permeable Peptides into the Nuclei of Intact Cells by Covalently Attached Nuclear Localization Signals," Biochemistry (2002) 41(29):9208-9214.
539	Harry O'Kuru, R.E. et al., "A Short, Flexible Route toward 2'-C-Branched Ribonucleosides," J. Org. Chem., 1997, 62(6), 1754-1759
540	Heasman, J., "Morpholino Oligos: Making Sense of Antisense?" Dev. Biol., 2002, 243, 209-214
541	Henderson, B. R. et al., "A Comparison of the Activity, Sequence Specificity, and CRM1-Dependence of Different Nuclear Export Signals," Exp. Cell Res. (2000) 256:213-224.
542	Hertel, et al., "Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides," J. Org. Chem., 1988, 53, 2406-2409.
543	Hill, F. et al., "Polymerase recognition of synthetic oligodeoxyribonucleotides incorporating degenerate pyrimidine and purine bases," Proc. Natl. Acad. Sci. USA, 1998, 95, 4258-4263
544	Hoffman, K., "Imidazole and its Derivatives" in The Chemistry of Heterocyclic Compounds, Weissberger, A., Ed.,Interscience Publishers, Inc., New York, 1953, 447
545	Holen, T., et al., "Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway," Nucleic Acids Res., 2003, 31(9), 2401-2407
546	Hornbeck, P. et al., Enzyme-Linked Immunosorbet Assays (ELIASE)," Curr. Protocols Mol. Biol., 1991, John Wiley & Sons, pp. 11.2.1-11.2.22

tubatituta far 1440/PTO		Complete if Known			
Substitute for 1449/PTO				Application Number	10/701,265
INFO	ORMATION	1 DISCLOS	SURE	Filing Date	11-04-2003
STATEMENT BY APPLICANT			CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	eets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	27	of	44	Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
547	Hornung, V. et al., "Sequence-specific potent induction of IFN-a by short ineterfering RNA in plasmacytoid dendritic cells through TLR7," Nature Med., 2005, 11(3), 263-270
548	Horton, N. C. et al., "The Structure of an RNA/DNA Hybrid: A Substrate of the Ribonuclease Activity of HIV-1 Reverse Transcriptase," J. Mol. Biol., 1996, 264, 521-533
549	Huang, L. et al., "Oligonucleotide conjugates of Eu(III) tetraazamacrocycles with pendent alcohol and amide groups promote sequence-specific RNA cleavage," J Biol Inorg. Chem (2000) 5:85-92.
550	Huh, N. et al., "Design, Synthesis, and Evaluation of Mitomycin-Tethered Phosphorothioate Oligodeoxynucleotides," Bioconjugate Chem. (1996) 7:659-669.
551	Hunter, "Genetics: a touch of elegance with RNAi," Current Biology, Current Science (1999) 9(12): R440-R442
552	Ikehara, et al, "Studies of Nucleosides and Nucleotides-LXV' Purine Cyclonucleosides-26 A Versatile Method for the Synthesis of Purine O-Cyclo-Bucleosides. The First Synthesis of 8,2'Anhydro-8-Oxy 9-B-D-Arabinofuranosylguanine," Tetrahedron, 1975, 31, 1369-1372
553	Ikehara, et al, "Studies of Nucleosides and Nucleotides-LXXXVII. 1, Purine Cyclonucleosides. XLII. Synthesis of 2'deoxy-2'fluorofunaosine," Chem. And Pharm. Bull., 1981, 29, 1034-1038.
554	Ikehara, et al. "Purine cyclonucleosides. (43). Synthesis and properties of 2'halogen-2'deoxyguanosines 1," Chem and Pharm Bull., 1981, 29, 3281-3285
555	Ikehara, et al., "A Linear Relationship Between Electronegativity of 2'-Substituents and Conformation of Adenine Nucleosides," Tetrahedron Letters, 1979, 42, 4073-4076
556	Ikehara, et al., "Improved Synthesis of 2'-fluoro-2'deoxyadenosine and Synthesis and Carbon-13 NMR Spectrum of its 3',5'-cyclic Phosphate Derivative," Nucleosides & Nucleotides, 1983, 2, 373-385
557	Ikehara, et al., "Polynucleotides. L. synthesis and properties of poly (2'chloro-2'-deoxyadenylic acid) and poly (2'-bromo-2'-deoxyadenylic acid)", Nucleic Acids Res., 1978, 4, 4249-4260
558	Ikehara, et al., "Polynucleotides. LII. Synthesis and properties of poly (2'-deox-2'-fluoroadenylic acid)," Nucleic Acids Research, 1978, 5, 1877-1887
559	Ikehara, et al., "Polynucleotides. LVI. Synthesis and Properties of Poly(2'-deoxy-2'-fluoroinosinic Acid)", Nucleic Acids Res., 1978, 5, 3315-3324
560	Ikehara, et al., "Purine 8-Cyclonucleosides," Accts. Chem Res., 1969, 2, 47-53

0.1.00.0	Substitute for 1440/DTO		Complete if Known		
Substitute for 1449/PTO				Application Number	10/701,265
	RMATION			Filing Date	11-04-2003
STATEMENT BY APPLICANT				First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	28	of	44	Attorney Docket Number	ISIS-5300
	1	ı	l	1	1
		NON D	ATENT LITE	PATURE DOCUMENTS	

	NON PATENT LITERATURE DOCUMENTS
561	Ikehara, et al., "Studies of Nucleosides and Nucleotides-LXXIV1 Purine Cyclonucleosides34 A New Method for the Synthesis of 2'-substituted 2'-deoxyadenosines," Tetrahedron, 1978, 34, 1133-1138
562	Ikehara, et al., "Studies of Nucleosides and Nucleotides-LXXXII. 1 Cyclonucleosides. (39). 2 Synthesis and properties of 2'halogen-2'-deoxyadenosines," Chem. Pharm. Bull., 1978, 26, 2449-2453
563	Ikehara, M., "2'-substituted 2'-deoxypurineucleotides their conformation and properties," Heterocycles, 1984, 21(1), 75-90
564	Imazawa, et al., "Nucleosides and nucleotides. XII.1) Synthesis and properties of 2'-deoxy-2'-mercaptouridine and its derivates", Chem. Pharm. Bull., 1975, 23, 604-610
565	Inoue et al., "Sequence dependent hydrolysis of RNA using modified oligonucleotide splints and Rnase H", FEBS Lett., 1987, 215(2), 327-330
566	Inoue, et al., "Synthesis and hybridization studies on two complementary nona(2'-O-methyl) ribonucleotides", Nucleic Acid Res., 1987, 15, 6131-6148
567	International Search Report Dated August 23, 2004 for International Application No. PCT/US03/09808
568	International Search Report dated March 24, 2005 for International Application No. PCT/US03/35088
569	International Search Report dated November 18, 2004 for International Application No. PCT/US03/29294
570	Jacobson, K.A. et al., "Methanocarba Analogues of Purine Nucleosides as Potent and Selective Adenosine Receptor Agonists," J. Med. Chem., 2000, 43(11), 2196-2203
571	Jäger, A. et al., "Oligonucleotide N-alkylphosphoramidates: Synthesis and binding to polynucleotides", Biochemistry 1988, 27, 7237-7246
572	Janik, B., et al., "Synthesis and Properties of Poly 2'-Fluoro-2'-Deoxyuridylic Acid," Biochem. Biophys. Res. Comm., 1972, 46(3), 1153-1160
573	Jarvi, et al., "Synthesis and biological evaluation of dideoxunucleosides containing a difluoromethylene unit", Nucleosides & Nucleotides, 1989, 8, 1111-1114
574	Jaschke, A. et al., "Synthesis and properties of oligodeoxyribonucleotide-polyethyleneg lycol conjugates," Nucleic Acids Res. (1994) 22(22):4810-4817.
575	Jayaraman, et al., "Selective Inhibition of Escherichia Coli Protein Synthesis and Growth by Nonionic Oligonucleotides Complementary to the 3' end of 16S rRNA", Proc. Natl. Acad. Sci. USA 1981, 78(3), 1537-1541

0 1 (1) 1 1 1	Substitute for 1449/PTO		_	Complete if Known		
Substitute for 1	449/PTO			Application Number	10/701,265	
_	-	DISCLOS		Filing Date	11-04-2003	
STATEMENT BY APPLICANT				First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)	l	Examiner Name	Jennifer S. Pitrak	
Sheet	29	of	44	Attorney Docket Number	ISIS-5300	
'		ı	1	1	'	
		NON P	ATENT LITE	RATURE DOCUMENTS		

	NON PATENT LITERATURE DOCUMENTS	
576	Jen et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells, 2000, 18, 307-319	
577	Jones, et al., "4'-substituted nucleosides. 5. hydroxymethylation of nucleoside 5'-aldehydes", J. Org. Chem., 1979, 44, 1309-1317	
578	Jones, et al., "Transient protection: Efficient one-flask synthesis of protected deoxynucleosides", J. Am. Chem. Soc., 1982, 104, 1316-1319	
579	Jones, L.J. et al., "RNA Quantitation by Fluorescence-Based Solution Assay: RiboGreen Reagent Characterization," Anal. Biochem., 1998, 265, 368-374	
580	Jones, S.S. et al., "Migration of t-Butyldimethylsilyl Protecting Groups," J.C.S. Perkin 1, 1979, 2762-2764	
581	Juby, C. D. et al., "Facile Preparation of 3'0ligonucleotide-Peptide Conjugates," Tetrahedron Letters (1991) 32(7):879-882.	
582	Jungblut, P.R., et al., "Proteomics in human disease: cancer, heart and infectious diseases," Electrophoresis, 1999, 20, 2100-2110	
583	Jurecic, R., et al., "Long-distance DD-PCR and cDNA microarrays," Curr. Opin. Mocrobiol., 2000, 3, 316-321	
584	Kabanov, A.V.,"A new class of antivirals: antisense olgonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells", FEBS Letts., 1990, 259, 327-330	
585	Kawasaki, H/ et al., "Hesl is a target of MicroRNA-23 during retinoic-acid-induced neuronal differentation of NT2 cells," Nature (2003) 423: 838-842	
586	Khurshid et al., "The unique conformational stability of poly 2'-O-Ethyladenylic Acid," FEBS Letters, 1972, 28(1), 25	
587	Khvorova, A. et al., "Functional siRNAs Exhibit Strand Bias," Cell, 2003, 115(2), 209-216	
588	Kiaris, H. et al., "Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of U-87MG Human Gliobastoma in Nude mice," Neoplasia, 2000, 2(3), 242-250	
589	Kielanowska et al., "Preparation and properties of poly 2'-O-ethylcytidylic acid," Nucl. Acids Res., 1976, 3(3), 817-824	
590	Kingston, R.E. et al., "Calcium Phosphate Transfection", Current Protocols in Neuroscience, 1997, Supplement 1, A.1C.1 – A.1C.8	

Cubatituta far	1440/DTO			Сотр	lete if Known	
Substitute for 1449/PTO				Application Number	10/701,265	
INFO	RMATION	DISCLOS	SURE	Filing Date	11-04-2003	
STA	TEMENT B	3Y APPLIC	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary))	Examiner Name	Jennifer S. Pitrak	
Sheet	30	of	44	Attorney Docket Number	ISIS-5300	

	NON PATENT LITERATURE DOCUMENTS
591	Klopffer, A.E. et al., "Synthesis of 2'-Aminoalkyl-Substituted Fluorinated Nucleobases and Their Influence on the Kinetic Properties of Hammerhead Ribozymes," ChemBioChem (2004) 5: 707-716
592	Klopffer, A.E. et al., "The effect of universal fluorinated nucleobases on the catalytic activity of ribozymes," Nucleosides Nucleotides Nucleic Acids (2003) 22(5-8): 1347-1350
593	Knorre, et al., "Complementary-Addressed Sequence-Specific Modification of Nucleic Acids", Progress in Nucleic Acid Research and Molecular Biology 1985, 32, 291-321
594	Koole, et al., "Synthesis of phosphate-methylated DNA fragments using 9-fluorenylmethoxycarbonyl as transient base protecting group", J. Org. Chem., 1989, 54, 1657-1664
595	Koshkin, A.A., et al., "LNA (locked nucleic acid): an RNA mimic forming exceedingly stable LNA:LNA duplexes," J. Am. Chem. Soc., 1998, 120, 13252-13253
596	Koshkin, A.A., et al., "LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition," Tetrahedron, 1998, 54, 3607-3630
597	Kraynack, B.A. et al., "Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/elF2C2-dependent activity," RNA, 2006, 12, 163-176
598	Krieg, A. M. et al., "Uptake of Oligodeoxyribonucleotides by Lymphoid Cells Is Heterogeneous and Inducible," Antisense Research and Development (1991) 1:161-171.
599	Kroschwitz, J.I. (Ed.), The Concise Encyclopedia of Polymer Science and Engineering, John Wiley & Sons, 1990, 858-859
600	Krug, A., et al., "Synthesis of oligonucleotide probes containing 2'-deoxy-2'-fluoronucleosides for cleavage of RNA by RNase H," Biomed. Biochem. Acta, 1990, 49, 161-166
601	Krug, A., et al., "The behaviour of 2'-deoxy-2'-fluorouridine incorporated into oligonucleotides by the phosphoramidite approach," Nucleosides & Nucleotides, 1989, 8(8), 1473-1483
602	Kuijpers, W. H. A. et al., "Specific Recognition of Antibody-Oligonucleotide Conjugates by Radiolabeled Antisense Nucleotides: A Novel Approach for Two-Step Radioimmunotherapy of Cancer," Bioconjugate Chem. (1993) 4(1):94-102.
603	Kumar et al., "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes," Microbiology and Molecular Biology Reviews (1998) 62(4): 1415-1434
604	Kumar, R., et al., "The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA," Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222

0 1 111 1 5 4	ubetitute for 1449/PTO		Complete if Known		
ubstitute for 1449/PTO				Application Number	10/701,265
INFO	RMATION	I DISCLOS	SURE	Filing Date	11-04-2003
STATEMENT BY APPLICANT			CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	eets as necessary))	Examiner Name	Jennifer S. Pitrak
Sheet	31	of	44	Attorney Docket Number	ISIS-5300
'			1	·	1
		NON F	PATENT LIT	ERATURE DOCUMENTS	

	NON PATENT LITERATURE DOCUMENTS
605	Kurchavov, N.A., et al., "A new phosphoramidite reagent for the incorporation of diazaphenoxazinone nucleoside with enhanced base-pairing properties into oligodeoxynucleotides," Nucleosides and Nucleotides, 1997, 16, 1837-1846
606	Kurreck, J., "Antisense technologies, Improvement through novel chemical modifications," Eur. J. Biochem., 2003, 270(8), 1628-1644
607	Kusmierek et al., "Alkyation of cytidine-5'-phosphate: Mechanisms of alkylation, influence of O'-alkylation on susceptibility of pyrimidine nucleotides to some nucleolytic enzymes, and synthesis of 2'-O-alkyl polynucleotides," ACTA Biochim. Polonica, 1973, 20(4), 365-381
608	Lacerra, G., et al., "Restoration of hemoglobin a synthesis in erythroid cells from peripheral blood of thalassemic patients," Proc. Natl. Acad. Sci. USA, August 15, 2000, 97(17), 9591-9596
609	Lai J. S. et al., "Fluorinated DNA Bases as Probes of Electrostatic Effects in DNA Base Stacking," Angew. Chem. Int. Ed. (2003) 42: 5973-5977
610	Lai, J. S. et al., "Selective Pairing of Polyfluorinated DNA Bases," J. Am. Chem. Soc. (2004) 126(10): 3040-3041
611	Lane, A. N. et al., "NMR Assignments and Solution Conformation of the DNA-RNA Hybrid Duplex d(GTGAACTT)-r(AAGUUCAC)," Eur. J. Biochem., 1993, 215, 297-306
612	Larson, E.J., et al., "Rapid DNA fingerprinting of pathogens by flow cytometry," Cytometry, 2000, 41, 203-208
613	Larsson, M., et al., "High-throughput protein expression of cDNA products as a tool in functional genomics," J. Biotechnol., 2000, 80, 143-157
614	Le Doan et al., "Sequence-Targeted Chemical Modifications of Nucleic Acids by Complementary Oligonucleotides Covalently Linked to Porphyrins", Nucleic Acid Research, 1987, 15, 8643-8659
615	Lee, R.C. et al., "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14," Cell, 1993, 75(5), 843-854
616	Lee, K. et al., "Ring-Constrained (N)-Methanocarba Nucleosides as Adenosine Receptor Agonists: Independent 5'-Uronamide and 2'-Deoxy Modifications," Bioorganic & Medicinal Chemistry Letters, 2001, 11(10), 1333-1337
617	Lee, Y. et al., "MicroRNA maturation: stepwise processing and subcellular localization," EMBO J. (2002) 21(17): 4663-4670
618	Lee, Y. et al., "The nuclearRNase III Drosha initiates microRNA processing," Nature (2003) 425: 415-419

	Cubalituda for 1440/DTO			Complete if Known		
Substitute for 1449/PTO				Application Number	10/701,265	
I	RMATION			Filing Date	11-04-2003	
STAT	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	32	of	44	Attorney Docket Number	ISIS-5300	
•	•		!	•	•	

	NON PATENT LITERATURE DOCUMENTS	
619	Leeds, J.M. et al., "Pharmacokinetic Properties of Phosphorothioate Oligonucleotides," Nucleosides Nucleotides, 1997, 16(7-9), 1689-1693	
620	Letsinger et al., "Effects of Pendant Groups at Phosphorus on Binding Properties of D-ApA Analogues", Nucleic Acids Research, 1986, 14, 3487-3499	
621	Letsinger, R.L. et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture", Proc. Natl. Acad. Sci.,1989, 86, 6553-6556	
622	Lewis, D.L. et al., "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," Nature Genetics, 2002, 32, 107-108	
623	Li, S. et al., "Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells," Pharm. Res. (1998) 15(10):1540-1545.	
624	Lima, W. F. et al., "Highly efficient endonucleolytic cleavage of RNA by a CyszHisz zinc-finger peptide," Proc. Natl. Acad. Sci. USA (1999) 96:10010-10015.	
625	Lima, W.F. et al., "Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids," Biochemistry, Vol. 36, pages 390-398 (1997)	
626	Limbach, P.A. et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Res., 1994, 22(12), 2183-2196	
627	Lin, KY. et al., "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acids," J. Am. Chem. Soc., 1998, 120(33), 8531-8532	
628	Lin, KY. et al., "Tricyclic 2'-Deoxycytidine Analogs: Synthesis and Incorporation into Oligodeoxynucleotides Which Have Enhanced Binding to Complementary RNA," J. Am. Chem. Soc., 1995, 117, 3873-3874	
629	Lin, M. et al., "Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts," Faseb J. 1995, 9, 1371-1377	
630	Liu, H. et al."A Four Base Paired Genetic Helix with Expanded Size," Science (2003) 302; 868-871	
631	Liu, H. et al., "Toward a New Genetic System with Expanded Dimensions: Size-Expanded Analogues of Deoxyadenosine and Thymidine," J. Am Chem Soc. (2004) 126(4) 1102-1109	
632	Liu, K. et al., "Efficient Nuclear Delivery of Antisense Oligodeoxynucleotides and Selective Inhibition of CETP Expression by Apo E Peptide in a Human CETP-Stably Transfected CHO Cell Line," Arterioscler. Thromb. Vasc. Biol. (1999) 19:2207-2213.	

	0.1.4% (Complete if Known	
Substitute for	1449/PTO			Application Number	10/701,265
	PRMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	33	of	44	Attorney Docket Number	ISIS-5300
•		'		ı	'

	NON PATENT LITERATURE DOCUMENTS
633	Lixin, R. et al., "Novel Properties of the Nucleolar Targeting Signal of Human Angiogenin," Biochem. Biophys. Res. Comm. (2001) 284:185-193.
634	Loakes, D. et al., "The applications of universal DNA base analogues," Nucleic Acids Res., 2001, 29(12), 2437-2447
635	Lukhtanov, E. A. et al., "Direct, Solid Phase Assembly of Dihydropyrroloindole Peptides with Conjugated Oligonucleotides," Bioconjugate Chem. (1996) 7(5):564-567.
636	Madden, S.L., et al., "Serial analysis of gene expression: from gene discovery to target identification," Drug Discov. Today, September 2000, 5(9), 415-425
637	Mahato et al., "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA," Expert Opinion on Drug Delivery, Jan. 2005, 2(1), 3-28
638	Manche et al., "Interactions between double-stranded RNA regulators and the protein kinase DAI," Mol. Cell Biol., 1992, 12(11), 5238-5248
639	Manoharan M. et al., "Cholic Acid-Oligonucliotide Conjugates for Antisense Applications", Bioorganic Med. Chem. Letts., 1994, 4, 1053-1060
640	Manoharan M. et al., "Oligonucleotide Conjugates: Alteration of the Pharmacokinetic Properties of Antisense Agents", Nucleosides and Nucleotides, 1995, 14, 969-973
641	Manoharan, M. et al., "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides", Annals NY Acad. Sciences, 1992, 660, 306-309
642	Manoharan, M. et al., "Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications", Bioorg. Med. Chem. Letts., 1993, 3, 2765-2770
643	Manoharan, M. et al., "Novel Functionalization of the Sugar Moiety of Nucleic Acids for Multiple Labeling in the Minor Groove," Tetrahedron Letters (1991) 32(49):7171-7174.
644	Manoharan, M. et al., "Lipidic Nucleic Acids", Tetrahedron Letts., 1995, 36, 3651-3654
645	Manoharan, M., "2'-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation," Biochimica et Biophysica Acta, 1999, 1489, 117-130
646	Manoharan, M., "Designer Antisense Oligonucleotides: Conjugation Chemistry and Functionality Placement," Antisense Research and Applications, Crooke and Lebleu, eds., CRC Press Boca Raton. FL, 1993, Chapter 17, 303-349.

0 1 111 1 1	Substitute for 1449/PTO			Complete if Known		
Substitute for				Application Number	10/701,265	
INFC	RMATION	DISCLOS	SURE	Filing Date	11-04-2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak	
Sheet	34	of	44	Attorney Docket Number	ISIS-5300	
	1	l	l	1	1	

	NON PATENT LITERATURE DOCUMENTS	
647	Manoharan, M., "Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery and Mechanism of Action," Antisense & Nucleic Acid Drug Development (2002) 12:103-128.	
648	Manoharan, M., "Oligonucleotide Conjugates in Antisense Technology," Antisense Drug Technology, Principles, Strategies, and Applications, Crooke, S. T. ed., Marcel Dekker, New York, (2001) Chapter 16, 391-467.	
649	Manoharan, M., "RNA interference and chemically modified small interfering RNAs," Current Opinion in Chemical Biology, 2004, 8, 570-579	
650	Marcus-Sekura, "Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages", Nucleic Acids Res., 1987, 15, 5749-5763	
651	Marcus-Sekura, "Techniques for Using Antisense Oligodeoxyribonucleotides to Study Gene Expression", Anal. Biochemistry, 1988, 172, 289-295	
652	Markiewicz, et al., "Simultaneous Protection of 3'- and 5'-Hydroxyl Groups of Nucleosides", Nucleic Acid Chemistry, Part 3, pgs. 229-231, L.B. Townsend, et al., Eds., J. Wiley and Sons, New York, 1986, 229-231	
653	Maruenda, H. et al., "Antisense Sequence-Directed Cross-Linking of DNA Oligonucleotides by Mitomycin C," Bioconjugate Chem. (1996) 7(5):541-544.	
654	Maruenda, H. et al., "Antisense sequence-directed cross-linking of RNA oligonucleotides by mitomycin," Anti-Cancer Drug. Des. (1997) 12, 473-479	
655	Marwick, C., "First "Antisense" Drug Will Treat CMV Retinitis," J. Am. Med. Assoc., 1998, 280(10), 871	
656	Matsukura, M. et al., "Phosphorothioate Analogs of Oligodeoxynucleotides: Inhibitors of Replication and Cytopathic Effects of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA, 1987, 84, 7706-7710	
657	Matteucci, M.D. et al., "Synthesis of Deoxyoligonucleotides on a Polymer Support," J. Am. Chem. Soc., 1981, 103(11), 3185-3191	
658	McCafferey, A.P. et al., "RNA interference in adult mice," Nature, 2002, 418, 38-39	
659	McIntyre, K.W. et al., "A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-kB p65 Causes Sequence-Specific Immune Stimulation," Antisense Res. Dev., 1993, 3, 309-322	
660	McQueen, C.A. et al., "Effect of Nalidixic Acid on DNA Repair in Rat Hepatocytes," Cell Biol. Toxicol., 1989, 5(2), 201-206	

Substitute for 1449/PTO				Complete if Known		
				Application Number	10/701,265	
	RMATION			Filing Date	11-04-2003	
STA	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak	
Sheet	35	of	44	Attorney Docket Number	ISIS-5300	
Sheet	35	of	44	Attorney Docket Number	ISIS-5300	

	NON PATENT LITERATURE DOCUMENTS	
661	Meunier, L. et al., "The nuclear export signal-dependent localization of oligonucleopeptides enhances the inhibition of the protein expression from a gene transcribed in cytosol," Nucleic Acids Res. 1999, 27(13):2730-2736	
662	Meyer, et al., "Efficient, Specific Cross-Linking and Cleavage of DNA by Stable, Synthetic Complementary Oligodeoxynucleotides", J. Am. Chem. Soc. 1989, 111, 8517-8519	
663	Mili, S. et al., "Distinct RNP Complexes of Shuttling hnRNP Proteins with Pre-mRNA and rnRNA. Candidate Intermediates in Formation and Export of mRNA," Mol. Cell Biol. (2001) 21(21):7307-7319.	
664	Miller, et al., "A New Approach to Chemotherapy Based on Molecular Biology and Nucleic Acid Chemistry: Matagen (Masking Tape for Gene Expression", Anti-Cancer Drug Design, 1987, 2, 117-128	
665	Miller, et al., "Biochemical and Biological Effects of Nonionic Nucleic Acid Methylphosphonates", Biochemistry 1981, 20, 1874-1880	
666	Miller, et al., "Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates", Biochemistry 1979, 18, 5134-5143	
667	Miller, et al., "Synthesis and properties of adenine and thymine nucleoside alkyl phosphotriesters, the neutral analogs of dinucleoside monophosphates", J. Am. Chem. Soc. 1971, 93, 6657-6664	
668	Min, KL. et al., "Oligonucleotides comprised of alternating 2' -deoxy-2' -fluoro-beta-D-arabinonucleosides and D-2' -deoxyribonucleosides (2'F-ANA/DNA 'Altimers') induce efficient RNA cleavage mediated by RNase H," Bioorganic & Medicinal Chemistry Letters, September 2002, 12, 2651-2654	
669	Mishra et al., "Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-medicated delivery", Biochim. Biophys. Acta, 1995, 1264, 229-237	
670	Miura et al., "Fluorometric determination of total mRNA with oligo(dT) immobized on microtiter plates", Clin. Chem., 1996, 42(11), 1758-1764	
671	Moran, S. et al., "A thymidine triphosphate shape analog lacking watson-crick pairing ability is replicated with high sequence selectivity," Proc. Natl. Acad. Sci. USA (1997) 94, 10506-10511	
672	Moran, S. et al., "Difluorotoluene, a Nonpolar Isostere for Thymine, Codes Specifically and Efficiently for Adenine in DNA Replication," J Am Chem Soc. (1997) 119(8), 2056-2057	
673	Morita, K. et al., "2'-O,4'-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodyamically Stable Oligonucleotides for Antisense Drug," Bioorganic & Medicinal Chemistry Letters, 2002, 12(1), 73-76	

Substitute for 1449/PTO INFORMATION DISCLOSURE				Complete if Known	
				Application Number	10/701,265
				Filing Date	11-04-2003
STATEMENT BY APPLICANT			CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	eets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	36	of	44	Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS	
674	Morita, K. et al., "Synthesis and Properties of 2'-0,4'-C-Ethylene-Bridged Nucleic Acids (ENA) as Effective Antisense Oligonucleotides," Bioorg. Med. Chem., 2003, 11, 2211-2226	
675	Moulds, C. et al., "Site and Mechanism of Antisense Inhibition by C-5 Propyne Oligonucleotides," Biochemistry, 1995, 34(15), 5044-5053	
676	Nasevicius, A. et al., "Effective targeted gene 'knockdown' in zebrafish," Nature Genetics, 2000, 26, 216-220	
677	NELSON, P. S. et al., "Bifunctional oligonucleotide probes synthesized using a novel CPG support are able to detect single base pair mutations," Nucleic Acids Res. (1989) 17(18):7187-7194	
678	Nestle, F.O. et al., "Cationic Lipid is not Required for Uptake and Selective Inhibitory Activity of ICAM-1 Phosphorothioate Antisense Oligonucleotides in Keratinocytes," J. Invest. Dermatol., 1994, 103, 569-575	
679	Nielsen et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide", Science, 1991, 254, 1497-1500	
680	Nykänen, A. et al, "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," Cell, 2001, 107, 309-321	
681	Oberhauser et al., "Effective incorporation of 2'-O-methyl-oligonucleotides into liposomes and enhanced cell association through modification with thiocholesterol", Nucl. Acids Res., 1992, 20(3), 533-538	
682	Ogilvie, K.K. et al., "The Use of Silyl Groups in Protecting the Hydroxyl Functions of Ribonucleosides," Tetrahedron Letters, 1974, 15(33), 2861-2863	
683	Ohtsuka et al., "Recognition By Restriction Endonuclease EcoRI of Deoxyoctanucleotides containing modified sugar moieties," Eur. J. Biochem., Mar. 1984, 447-450	
684	Olie, R.A. et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," Biochimica et Biophysica Acta, 1576 (2002), 101-109	
685	Olsen, D.B., et al., "Study of a Hammerhead Ribozyme Containing 2'-Modified Adenosine Residues," Biochemistry, 1991, 30:, 9735-9741	
686	O'Neill, B.M. et al., "A Highly Effective Nonpolar Isostere of Deoxyguanosine: Synthesis, Structure, Stacking, and Base Pairing," J. Org. Chem. (2002) 67(17):5869-5875	
687	Opalinska et al., "Nucleic-acid therapeutics: basic principles and recent applications," Nature Review, 2002, 1, 503-514	
688	Ørum, H. et al., "Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development," Curr. Opin. Mol. Therap., 2001, 3(3), 239-243	

Substitute for 1449/PTO				Complete if Known	
				Application Number	10/701,265
INFORMATION DISCLOSURE				Filing Date	11-04-2003
STATEMENT BY APPLICANT			CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	eets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	37	of	44	Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS	
689	Outten, et al., "Synthetic 1-methoxybenzo[d]naphtho[1,2-b]pyran-6-one c-glycosides", J. Org. Chem. 1987, 52, 5064-5066	
690	Owen, et al., "Transcriptional activation of a conserved sequence element by ras requires a nuclear factor distinct from c-fos or c-jun", Proc. Natl. Acad. Sci USA, 1990, 87, 3866-3870	
691	Owen, G.R. et al., "4'-Substituted Nucleosides. 3. Synthesis of Some 4'-Fluorouridine Derivatives," J. Org. Chem., 1976, 41(18), 3010-3017	
692	Parker, J.S. et al., "Structure insights into mRNA recognition from a PIWI domain-siRNA guide complex," Nature, 2005, 434, 663-666	
693	Parkes, et al., "A short synthesis of 3'-cyano-3'-Deoxythymidine", Tetra. Lett., 1988, 29, 2995-2996	
694	Parr, W. et al., "Solid-Phase Peptide Synthesis on an Inorganic Matrix having Organic Groups on the Surface," Angew Chem. Internat. Edit, 1972, 11 (4), 314-315	
695	Patzel et al., "A Theoretical Approach to Select Effective Antisense Oligodeoxyribonucleotides at High Statistical Probability," Nucleic Acids Research (1999) pp. 4328-4334.	
696	Peracchi, A., "Prospects for antiviral ribozymes and deoxyribozymes," Rev. Med. Virol., Vol. 14, pages 47-64 (2004).	
697	Petersen, M. et al., "The conformations of locked nucleic acids (LNA)," J. Mol. Recognit., 2000, 13, 44-53	
698	Petersheim, et al., "Base-Stacking and Base-Pairing contributions to helix stability: thermodynamics of double-helix formation with CCGG, CCGGp, CCGGAp, ACCGGp, CCGGUp, and ACCGGUp", Biochemistry, 1983, 22, 256-263	
699	Pichon, C. et al., "Intracellular Routing and Inhibitory Activity of Oligonucleopeptides Containing a KDEL Motif," Mol. Pharmacol. (1997) 51:431-438.	
700	Pieken, W.A., et al., "Structure-Function Relationship of Hammerhead Ribozymes as Probed by 2'-Modifications," Nucleic Acids Symp Ser., 1991, 24, 51-53	
701	Pike et al., "Mixed Alkylation (Methylation and Ethylation) of Adenosine by Diazoethane in Aqueous 1,2-Dimethoxyethane," J. Org. Chem., 1974, 39(25), 3674-3676	
702	Pitts, A.E. et al., "Inhibition of human telomerase by 2'-O-methyl-RNA," Proc. Natl. Acad. Sci. USA, 1998, 95, 11549-11554	
703	Poopeiko, N.E. et al., "Xylo-configured Oligonucleotides (XNA, Xylo Nucleic Acid): Synthesis of Conformationally Restricted Derivatives and Hybridization Towards DNA and RNA Complements," Biorganic & Medicinal Chemistry Letters 2003, vol. 13, pages 2285-2290	

	0.1.17.1.1.1.14440/DT0			Complete if Known	
Substitute for	1449/PTO			Application Number	10/701,265
	RMATION			Filing Date	11-04-2003
STA	TEMENT E	BY APPLIC	ANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
Sheet	38	of	44	Attorney Docket Number	ISIS-5300
•	•			ı	'

	NON PATENT LITERATURE DOCUMENTS
704	Prakash, T. P. et al., Abstract of The 227th ACS National Meeting, Anaheim,CA, March 28-April 1, 2004
705	Prakash, T. P. et al., "Synthesis of Site-Specific Oligonucleotide-Polyamine Conjugates," Bioorg. Med. Chem. Lett. (1994) 4(14):1733-1738.
706	Prashar, Y., et al., "A method for display of 3'-end fragments of restriction enzyme-digested cDnAs for analysis of differential gene expression," Methods Enzymol., 1999, 303, 258-272
707	Puglisi, et al., "Absorbance melting curves of RNA", Methods in Enzymology, 1989, 180, 304-325
708	Rajur, S. B. et al., "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules," Bioconjugate Chem. (1997) 8(6):935-940.
709	Ranganathan, "Modification of the 21-Position of Purine Nucleosides: Synthesis of 21-a-Substituted-21-Deoxyadenosine Analogs", Tetrahedron Letters, 1977, 15, 1291-1294
710	Ransford et al., "2'-O-Ethyl Pyrimidine Nucleosides," J. Carbohydrates - Nucleosides - Nucleotides, 1974, 1(3), 275-278
711	Rao, et al., "A Novel One-step Procedure for the Conversion of Thymidine into 2,3'-Anhydrothymidine", J. Chem. Soc. Chem. Commun., 1989, 997-998
712	Rausch, J.W. et al., "Hydrolysis of RNA/DNA hybrids containing nonpolar pyrimidine isosteres defines regions essential for HIV type 1 polypurine tract selection," PNAS (2003) 100(20): 11279-11284
713	Reddy, M.P. et al., "Fast Cleavage and Deprotection of Oligonucleotides," Tetrahedron Letters, 1994, 35(25), 4311-4314
714	Reese, C.B., et al., "4-(1,2,4-Triazol-1-yl)-and 4-(3-Nitro-1,2,4-triazol-1-yl)-1-(β-D-Arabinofuranosyl)cytosine(Ara-C)", J. Chem. Soc. Perkin Trans. I, 1982, pgs. 1171-1176
715	Renneberg, D. et al. "Antisense properties of tricyclo-DNA," Nucleic Acids Res., 2002, 30(13), 2751-2757
716	Renneberg, D., et al., "Watson—Crick base-pairing properties of tricycle-DNA," J. Am. Chem. Soc., 2002, 124, 5993-6002
717	Revankar et al., "Synthesis and Antiviral/Antitumor of Certain 3-Seazaguanine Nucleosides and Nucleotides", J. Med. Chem. 1984, 24, 1389-1396
718	Rhodes, J. et al., "Therapeutic potentiation of the immune system by costimulatory Schiffbaseforming drugs," Nature (1995) 377(6544):71-75.

				Comp	lete if Known	
Substitute for 1449/PTO				Application Number	10/701,265	
INFO	RMATION	DISCLO	SURE	Filing Date	11-04-2003	
STAT	TEMENT E	Y APPLI	CANT	First Named Inventor	Brenda F. Baker	
				Art Unit	1635	
	(use as many she	ets as necessary	<i>(</i>)	Examiner Name	Jennifer S. Pitrak	
Sheet	39	of	44	Attorney Docket Number	ISIS-5300	
		NON I	PATENT LIT	ERATURE DOCUMENTS		
719	Deoxygen	ation of Seco	ndary Alcohol	Compounds. 42. A General P s. Regiospecific and Stereose des", J. Am. Chem. Soc., 198	elective Conversion of	
720		Robins, et al., "Synthesis of 2'-Deoxytubercidin, 2'-Deoxyadenosine, and Related 2'-				

	NON PATENT LITERATURE DOCUMENTS
719	Robins, et al., "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides", J. Am. Chem. Soc., 1983, 105, 4059-4065
720	Robins, et al., "Synthesis of 2'-Deoxytubercidin, 2'-Deoxyadenosine, and Related 2'-Deoxynucleosides via a Novel Direct Stereospecific Sodium Salt Glycosylation Procedure", J. Am. Chem. Soc., 1984, 106, 6379-6382
721	Roelen et al., "Synthesis of Nucleic Acid Methylphos-Phonothioates", Nucleic Acids Research 1988, 16(15), 7633-7645
722	Rottman et al., "Influence of 2'-O-Alkylation on the Structure of Single-Stranded Polynucleotides and the Stability of 2'-O-Alkylated Polynucleotide Complexes," Biochem., 1974, 13, 2762-2771
723	Ruby, et al., "An Early Hierarchic Role of U1 Small Nuclear Ribonucleoprotein in Splicesome Assembly", Science, 1988, 242, 1028-1035
724	Rump, E. T. et al., "Preparation of Conjugates of Oligodeoxynucleotides and Lipid Structures and Their interaction with Low-Density Lipoprotein," Bioconjugate Chem. (1998) 9(3):341-349.
725	Ryan, et al., "Synthesis of 2-Thio-D-ribose and 2'-Thioadenosine Derivatives", J. Org. Chem., 1971, 36(18), 2646-2657
726	Sambrook, et al., "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Laboratory Press, 1989, Vol. 2, pgs. 11.31-11.32
727	San et al., "Safety and short term toxicity of a novel cationic lipid formulation for human gene therapy", Human Gene Therapy, 1993, 4, 781-788
728	Sanghvi, Y.S. et al., "Heterocyclic Base Modifications in Nucleic acids and their Applications in Antisense Oligonucleotides", Antisense Research and Applications, CRC Press, Boca Raton, Chapter 15, 1993, 273-288
729	Scaringe, S.A. et al., "Novel RNA Synthesis Method Using 5'-O-Silyl-2'-O-orthoester Protecting Groups," J. Am. Chem. Soc., 1998, 120(45), 11820-11821
730	Scaringe, S.A., "RNA Oligonucleotide Synthesis via 5'-Silyl-2'-Orthoester Chemistry," Methods, 2001, 23, 206-217
731	Scaringe, S.A., Thesis entitled, "Design and Development of New Protecting Groups for RNA Synthesis," University of Colorado (1996)
732	Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," Nat. Biotechnol., 2003, 21(12), 1457-1465

Substitute for 1449/PTO		Complete if Known			
		Application Number	10/701,265		
INFO	ORMATION	I DISCLO	SURE	Filing Date	11-04-2003
STATEMENT BY APPLICANT			CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessar,	<i>(</i>)	Examiner Name	Jennifer S. Pitrak
Sheet	l' l j'l			Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
733	Schöning, KU., et al., "Chemical etiology of nucleic acid structure: the α-threofuranosyl-(3'→2') oligonucleotide system," Science, 2000, 290, 1347-1351
734	Schwartz, et al., "A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity", Gene, 1990, 88, 197-205
735	Schwartz, M.E. et al., "Rapid Synthesis of Oligoribonucleotides Using 2'-O-(o-Nitrobenzyloxymethyl)-Protected Monomers," Bioorg. Med. Chem. Lett., 1992, 2(9), 1019-1024
736	Schwarz, D.S. et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," Cell, 2003, 115(2), 199-208
737	Searle, M. S. et al., "On the Stability of Nucleic Acid Structures in Solution: Enthalpy-Entropy Compensations, Internal Rotations and Reversibility," Nucl. Acids Res., 1993, 21(9), 2051-2056
738	Seela, et al., "Palindromic Octa- and Dodecanucleotides Containing 2'-Deoxytubercidin: Synthesis, Hairpin Formation, and Recognition by the Endodeoxyribonuclease", Biochemistry, 1987, 26, 2232-2238
739	Seliger, H., et al., "Synthetic Oligonucleotides for Biomedical Applications," Nucleic Acids Symp Ser., 1991, 24:193-196
740	Shea et al., "Synthesis, hybridization properties and antiviral activity of lipid- oligodeoxynucletide conjugates", Nucl. Acids Res., 1990, 18(13), 3777-3783
741	Sheehan, D. et al., "Biochemical properties of phosphonoacetate and thiophosphonoactate oligodeoxyribonucleotides," Nucleic Acids Res., 2003, 31(14), 4109-4118
742	Shi, Y., "Mammalian RNAi for the masses," Trends in Genetics (2003) 19(1): 9-12
743	Sigman, "Nuclease Activity of 1,10-Phenanthroline-Copper Ion", Acc. Chem. Res., 1986, 19, 180-186
744	Singer et al., "Alkylation of Ribose in RNA Reacted with Ethylnitrosourea at Neutrality," Biochem., 1976, 15(23), 5052
745	Singh, S.K. et al., "LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition," Chem. Commun., 1998, 4, 455-456
746	Singh, S.K., et al., "Synthesis of 2'-amino-LNA: a novel conformationally restricted high-affinity oligonucleotide analogue with a handle," J. Org. Chem., 1998, 63, 10035-10039
747	Skorski, T. et al., "Antileukemia effect of c-myc N3'P5' phosphoramidate antisense oligonucleotides in vivo," Proc. Natl. Acad. Sci. USA, 1997, 94, 3966-3971

0 111 1 1 1 1 1 1 1 1		Complete if Known			
Substitute for 1449/PTO				Application Number	10/701,265
	RMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
(use as many sheets as necessary)				Examiner Name	Jennifer S. Pitrak
Sheet	Sheet 41 of 44			Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
748	Smith et al., "Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5", Proc. Natl. Acad. Sci. USA, 1986, 83, 2787-2791
749	Smith, T.F. et al., "Comparison of Biosequences," Adv. Appl. Math., 1981, 2, 482-489
750	Song, E. et al., "RNA interference targeting Fas protects mice from fulmiant hepatitis," Nature Med., 2003, 9(3), 347-351
751	Song, JJ. et al., "The Crystal Structure of Argonaute and Its Implication for RISC Slicer Activity," Science, 2004, 305, 1434-1437
752	Song, JJ. et al., "The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes," Nature Struct. Biol., 2003, 10(12), 1026-1032
753	Soutschek, J. et al., "Therapeutic silencing of a endogenous gene by systemic administration of modified siRNAs," Nature, 2004, 432(7014), 173-178
754	Sproat, et al., "Highly Efficient Chemical Synthesis of 2'-O-methylioligoribunocleotides and Tetrabiotinylated Derivatives; Novel Probes That are Resistant to Degradation by RNA or DNA Specific Nucleases", Nucleic Acids Research, 1989, 17, 3373-3386
755	Sproat, et al., "New synthetic routes to protected purine 2'-O-methylriboside-3'-O-phosphoramidites using a novel alkylation procedure", Nucleic Acids Research, 1990, 18, 41-49
750	Steffens, R., et al., "168. Nucleic-acid analogs with constraint conformational flexibility in the sugar-phosphate backbone "tricycle-DNA'," Helv. Chim. Acta, 1997, 80, 2426-2439
75	Stein, et al., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review", Cancer Research, 1988, 48, 2659-2668
758	Stein, et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research, 1988, 16, 3209-3221
759	Struck, "Vaccine R&D Success Rates and Development Times," Nature Biotechnology, May 1996, 14, 591-593
760	Stufkens, et al., "Dynamic Jahn-Teller Effect in the Excited States of SeCl62-, SeBr62-, TeCl62- and TeBr62-", Recueil des Travaux Chimiques des Pays-Bas 1970, 89, 1185-1201
761	Suciu et al., "Synthesis of 9-(2,5-dideoxy-β-D-glycero-pent-4-enofuranosyl)adenine", Carbohydrate Research, 1975, 44, 112-115
762	Sutcliffe, J.G. et al., "TOGA: An automated parsing technology for analyzing expression of nearly all genes," PNAS, 2000, 97(5), 1976-1981

			Complete if Known		
Substitute for	1449/PTO			Application Number	10/701,265
	RMATION			Filing Date	11-04-2003
STA	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	42	of	44	Attorney Docket Number	ISIS-5300

NON PATENT LITERATURE DOCUMENTS
Svinarchuk, F.P. et al., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups," Biochimie, 1993, 75, 49-54
Tamanini, F. et al., "The fragile X-related proteins FXRIP and FXRZP contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins," Hum. Mol. Genet. (2000) 9(10):1487-1493
Tang, XQ. et al., "2'-C-Branched Ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-Beta-Methylcytidine and Their Incorporation into Oligonucleotides," J. Org. Chem., 1999, 64(3), 747-754
Tazawa et al., "A Novel Procedure for the Synthesis of 2'-O-Alkyl Nucleotides" Biochem., 1972, 11(26), 4931
Thompson," Applications of Antisense and siRNAs During Preclinical Drug Development," DDT (2002) 7(17): 912-917
Tidd, D.M. et al., "Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues," Anti-Cancer Drug Design, 1988, 3(2), 117-127
To, KY. "Identification of differential gene expression by high throughput analysis," Comb. Chem. & High Throughput Screen, 2000, 3, 235-241
U.S. Patent Application Serial No. 09/315,298 filed May 20, 1999, by Teng et al.
U.S. Patent Application Serial No. 60/423,760 filed November 5, 2002, by Baker et al.
Van der Krol, et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences", BioTechniques, 1988, 6, 958-976
Vickers, T.A. et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and Rnase H-dependent Antisense Agents," J. Biol. Chem., 2003, 278(9), 7108-7118
Wada, A. et al., "Nuclear export of actin: a novel mechanism regulating the subcellular localization of a major cytoskeletal protein," EMBO J. (1998) 17:1635-1641
Wahlestedt, C., et al., "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids," Proc. Natl. Acad. Sci. U.S.A., 2000, 97(10), 5633-5638
Walder, et al., "Antisense DNA and RNA: Progress and Prospects", Genes & Development, 1988, 2, 502-504
Walder, et al., "Role of RNase H in Hybrid-Arrested Translation by Antisense Oligonucleotides", Proc. Natl. Acad. Sci. USA 1988, 85, 5011-5015

Cultatituta fan 4.440/DTO		Compl	Complete if Known		
Substitute for 1449/PTO				Application Number	10/701,265
INFORMATION DISCLOSURE				Filing Date	11-04-2003
STATEMENT BY APPLICANT			ANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	43	of	44	Attorney Docket Number	ISIS-5300
	•	1		'	ı
		NON D	ATENT LITE	PATURE DOCUMENTS	

	NON PATENT LITERATURE DOCUMENTS
778	Wang, J., et al., "Syhthesis and binding property of an oligonucleotide containing tetrafluorophenoxazine," Tetrahedron Lett., 1998, 39, 8385-8388
779	Wang, X. et al., "Modular Recognition of RNA by a Human Pumilio-Homology Domain," Cell (2002) 110:501-512.
780	Wei, Z. et al., "Hybridization properties of oligodeoxynucleotide pairs bridged by polyarginine peptides," Nucleic Acids Res. (1996) 24(4):655-661.
781	Wein, G. et al., "The 3'-UTR of the mRNA coding for the major protein kinase C substrate MARCKS contains a novel CU-rich element interacting with MRNA stabilizing factors HuD and HuR," Eur. 1. Biochem. (2003) 270:350-365.
782	Wengel, J., et al., "LNA (locked nucleic acid)," Nucleosides, Nucleotides, 1999, 18(6 & 7), 1365-1370
783	Wianny et al., "Specific interference with gene function by double-stranded RNA in early mouse development," Nature Cell Biology (2000) 2: 70-75
784	Wilds, C.J., et al., "Duplex recognition by oligonucleotides containing 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxy-2'-fluoro-D-ribose. Intermolecular 2'-OH-phosphate contacts versus sugar puckering in the stabilization of triple-helical complexes," Bioconjugate Chem., 1999, 10, 299-305
785	Williams, D.M., et al., 'Properties of 2'-Fluorothymidine-Containing Oligonucleotides: Interaction with Restriction Endonuclease EcoRV," Biochemistry, 1991, 30, 4001-4009
786	Wolfe, S., et al., "The guache effect. Some stereochemical consequences of adjacent electron pairs and polar bonds," Acc. Of Chem. Res., 1972, 5, 102-111
787	Wouters, J. et al., "5-Substituted Pyrimidine 1,5-Anhydronhexitols: Conformational Analysis and Interaction with Viral Thymidine Kinase," Bioorg. Med. Chem. Lett., 1999, 9, 1563-1566
788	Wright, P. et al., "Large Scale Synthesis of Oligonucleotides via Phosphoramidite Nucleosides and a High-loaded Polystyrene Support," Tetrahedron Lett., 1993, 34(21), 3373-3376
789	Wu, H. et al., "Properties of Cloned and Expressed Human RNase H1," Journal of Biological Chemistry 1999, vol. 274, pages 28270-28278
790	Wu, X., et al., "Base-pairing systems related to TNA: α-threofuranosyl oligonucleotides containing phosphoramidate linkages," Organic Lett., 2002, 4(8), 1279-1282
791	Yang, Y. et al., "HIV-1 TAT-mediated protein transduction and subcellular localization using novel expression vectors," FEBS Letters (2002) 532, 36-44.
792	Yeung, et al., "Photoreactives and Thermal Properties of Psoralen Cross-Links", Biochemistry 1988, 27, 3204-3210

0 111 1 1 1 1 1 1 1 1		Complete if Known			
Substitute for 1449/PTO				Application Number	10/701,265
	RMATION			Filing Date	11-04-2003
STATEMENT BY APPLICANT			CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	44	of	44	Attorney Docket Number	ISIS-5300
•	•			'	'

	NON PATENT LITERATURE DOCUMENTS	
793	Zamecnik, P.C. et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," Proc. Natl. Acad. Sci. USA, 1978, 75(1), 280-284	
794	Zamore, P.D. et al., "Ancient Pathways Programmed by Small RNAs," Science, 2002, 296, 1265-1269	
795	Zamore, P.D. et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell, 2000, 101, 25-33	
796	Zanta, M. A. et al., "Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus," Proc. Natl. Acad. Sci. USA (1999) 96:91-96.	
797	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," Cell, 2004, 118, 57-68	
798	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology," Current Pharmaceutical Biotechnology, 2004, 5, 1-7	
799	Zhang, H. et al., "Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fuminant hepatitis," Nature Biotech., 2000, 18, 862-867	
800	Zhang, J., et al., "PowerBLAST: A new network BLAST application for interactive or automated sequence analysis and annotation," Genome Res., 1997, 7, 649-656	
801	Zhang, Z. et al., "Uptake of N-(4'-pyridoxyl)amines and release of amines by renal cells: A model for transporter-enhanced delivery of bioactive compounds," Proc. Natl. Acad. Sci. USA (1991) 88:10407-10410.	
802	Zhao, Q. et al., "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," Biochemical Pharmacology, 1996, 51, 173-182	
803	Zhu, T. et al., "Oligonucleotide-Poly-L-omithine Conjugates: Binding to Complementary DNA and RNA." Antisense Res. Dm. 119931 3:265-275.	
804	Zon, "Oligonucleotide Analogues as Potential Chemotherapy Agents", Pharm. Res., 1988, 5(9), 539-549	
805	Zon, "Synthesis of Backbone-Modified DNA Analogues for Biological Applications", J. Protein Chemistry, 1987, 6, 131-145	
806	Zuckermann, R. N. et al., "Site-Selective Cleavage of RNA by a Hybrid Enzyme," J. Am. Chem. SOC. (1988) 110:1614-1615.	